

## Désiré COLLEN

### Bibliography

#### I. Research articles

1. Tytgat G.N., Collen D.J., De Vreker R.A.  
La diathèse hémorragique en cas de cirrhose du foie.  
Nouv. Rev. Fr. d'Hématol. 8, 123-130, 1968.
2. Collen D., Tytgat G., Verstraete M.  
Semi-automatic method for routine evaluation of fibrinolytic components.  
J. Clin. Pathol. 21, 705-707, 1968.
3. Tytgat G., Piessens J., Collen D., De Grootte J.  
Experience with exchange transfusion in the treatment of hepatic coma.  
Digestion 1, 257-266, 1968.
4. Tytgat G., Collen D., De Vreker R., Verstraete M.  
Investigations on the fibrinolytic system in liver cirrhosis.  
Acta Hematol. 40, 265-274, 1968.
5. Collen D., Vandereycken G., De Maeyer L.  
Influence of hydrostatic pressure on the reversible polymerization of fibrin monomers.  
Nature 228, 669-671, 1970.
6. Piessens R., Collen D., Tytgat G.  
Computer analysis of fibrinogen tracer data.  
Comput. Biomed. Res. 4, 585-593, 1971.
7. Tytgat G.N., Collen D., Verstraete M.  
Metabolism of fibrinogen in cirrhosis of the liver.  
J. Clin. Invest. 50, 1690-1701, 1971.
8. Collen D., Tytgat G., Claeys H., Verstraete M., Wallén P.  
Metabolism of plasminogen in healthy subjects : effect of tranexamic acid .  
J. Clin. Invest. 51, 1310-1318, 1972.
9. Collen D., Tytgat G.N., Claeys H., Piessens R.  
Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans.  
Brit. J. Haematol. 22, 681-700, 1972.
10. Tytgat G.N., Collen D., Vermylen J.  
Metabolism and distribution of fibrinogen. II. Fibrinogen turnover in polycythaemia, thrombocytosis, haemophilia A, congenital afibrinogenaemia and during streptokinase therapy.  
Brit. J. Haematol. 22, 701-717, 1972.

11. Tytgat G.N., Collen D., Oei L.S., Van Damme B.  
Fibrinogen metabolism in healthy dogs and in dogs with CCl<sub>4</sub>-induced liver damage and with portal vein occlusion.  
Thromb. Diathes. haemorrh. 27, 319-336, 1972.
12. Collen D., Vermeylen J.  
Metabolism of iodine-labeled plasminogen during streptokinase and reptilase therapy in man.  
Thromb. Res. 2, 239-250, 1973.
13. Kudryk B.J., Collen D., Woods K.R., Blombäck B.  
Evidence for localization of polymerization sites in fibrinogen.  
J. Biol. Chem. 249, 3322-3325, 1974.
14. Collen D., De Cock F.  
Emergence in plasma during activation of the coagulation or fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors.  
Thromb. Res. 5, 777-779, 1974.
15. Rouvier J., Collen D., Swart A.C.W., Verstraete M.  
Prothrombin metabolism in healthy subjects and in two patients with congenital hypoprothrombinemia.  
In : Prothrombin and related coagulation factors. Ed.: Hemker H.C. and Veltkamp J.J., Boerhaave series for post-graduate medical education. Leiden University Press, The Netherlands, 1975, p. 167-182.
16. Collen D., Kudryk B., Hessel B., Blombäck B.  
Primary structure of human fibrinogen and fibrin. Isolation and partial characterization of chains of fragment D.  
J. Biol. Chem. 250, 5808-5817, 1975.
17. Collen D., Ong E.B., Johnson A.J.  
Human plasminogen: in vitro and in vivo evidence for the biological integrity of NH<sub>2</sub>-terminal glutamic acid plasminogen.  
Thromb. Res. 7, 515-529, 1975.
18. Collen D., De Cock F.  
A tanned red cell hemagglutination inhibition immunoassay (TRCHII) for the quantitative estimation of thrombin-antithrombin III and plasmin-alpha1-antiplasmin complexes in human plasma.  
Thromb. Res. 7, 235-238, 1975.
19. Collen D., De Cock F., Verstraete M.  
Immunochemical distinction between antiplasmin and alpha1-antitrypsin.  
Thromb. Res. 7, 245-249, 1975.

20. Telesforo P., Semeraro N., Verstraete M., Collen D.  
The inhibition of plasmin by antithrombin III-heparin complex in vitro in human plasma and during streptokinase therapy in man.  
Thromb. Res. 7, 669-676, 1975.
21. Collen D.  
Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.  
Eur. J. Biochem. 69, 209-216, 1976.
22. Edy J., De Cock F., Collen D.  
Inhibition of plasmin by normal and antiplasmin-depleted human plasma.  
Thromb. Res. 8, 513-518, 1976.
23. Hedner U., Collen D.  
Immunochemical distinction between the inhibitors of plasminogen activation and antiplasmin in human plasma.  
Thromb. Res. 8, 875-879, 1976.
24. Wiman B., Collen D.  
Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma.  
Eur. J. Biochem. 78, 19-26, 1977.
25. Collen D., De Cock F., Cambiaso C.L., Masson P.  
A latex agglutination test for rapid quantitative estimation of the plasmin-antiplasmin complex in human plasma.  
Eur. J. Clin. Invest. 7, 21-26, 1977.
26. Collen D., Verstraete M.  
Plasmin-antiplasmin complex formation during defibrase infusion in man.  
Thromb. Res. 11, 417-420, 1977.
27. Collen D., Schetz J., De Cock F., Holmer E., Verstraete M.  
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.  
Eur. J. Clin. Invest. 7, 27-35, 1977.
28. Semararo N., Collen D., Verstraete M.  
On the origin of the A $\alpha$  chain heterogeneity of human fibrinogen.  
Biochim. Biophys. Acta 492, 204-214, 1977.
29. Collen D., Semeraro N., Tricot J.P., Vermynen J.  
Turnover of fibrinogen, plasminogen and prothrombin during exercise in man.  
J. Appl. Physiol. 42, 865-873, 1977.

30. Collen D., Billiau A., Edy J., De Somer P.  
Identification of the human plasma protein which inhibits fibrinolysis associated with malignant cells.  
*Biochim. Biophys. Acta* 499, 194-201, 1977.
31. Edy J., Collen D.  
The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor with plasmin, thrombin, trypsin and chymotrypsin.  
*Biochim. Biophys. Acta* 484, 423-432, 1977.
32. Ohlsson K., Collen D.  
Comparison of the reactions of neutral granulocyte proteases with the major plasma protease inhibitors and with antiplasmin.  
*Scand. J. Clin. Lab. Invest.* 37, 345-350, 1977.
33. Collen D., De Cock F., Verstraete M.  
Quantitation of thrombin-antithrombin III complexes in human blood.  
*Eur. J. Clin. Invest.* 7, 407-411, 1977.
34. Wiman B., Collen D.  
On the kinetics of the reaction between human antiplasmin and plasmin.  
*Eur. J. Biochem.* 84, 573-578, 1978.
35. Rákóczi I., Wiman B., Collen D.  
On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin.  
*Biochim. Biophys. Acta* 540, 295-300, 1978.
36. Claeys H., Collen D.  
Purification and characterization of bovine coagulation factor XII (Hageman factor).  
*Eur. J. Biochem.* 87, 69-74, 1978.
37. Rákóczi I., Chamone D., Collen D., Verstraete M.  
Prediction of postoperative leg-vein thrombosis in gynaecological patients.  
*Lancet* i, 509-510, 1978.
38. Wiman B., Boman L., Collen D.  
On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasmin.  
*Eur. J. Biochem.* 87, 143-146, 1978.
39. Collen D., De Cock F.  
Neoantigenic expression in enzyme-inhibitor complexes : a means to demonstrate activation of enzyme systems.  
*Biochim. Biophys. Acta* 525, 287-290, 1978.

40. Bini A., Collen D.  
Measurement of plasmin-antiplasmin complex in plasma. A comparison of latex agglutination, latex agglutination inhibition and hemagglutination inhibition tests.  
*Thromb. Res.* 12, 389-395, 1978.
41. Semeraro N., Colucci M., Telesforo P., Collen D.  
Inhibition of plasmin by antithrombin-heparin complex. I. In human plasma in vitro.  
*Brit. J. Haematol.* 39, 91-99, 1978.
42. Collen D., Semeraro N., Telesforo P., Verstraete M.  
Inhibition of plasmin by antithrombin-heparin complex. II. During thrombolytic therapy in man.  
*Brit. J. Haematol.* 39, 101-110, 1978.
43. Criel A., Collen D., Masson P.L.  
A case of IgM antibodies which inhibit the contact activation of blood coagulation.  
*Thromb. Res.* 12, 883-892, 1978.
44. Semeraro N., Collen D.  
Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and fragment D.  
*Thromb. Res.* 12, 1059-1070, 1978.
45. Prandini M.H., Wiman B., Samama M., Collen D.  
Effects of the synthetic fibrinolytic agents ortho-thymotic acid and S-1623 on the reaction between human plasmin and antiplasmin.  
*Thromb. Res.* 13, 165-173, 1978.
46. Bini A., Semeraro N., Collen D.  
Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and on fragment D from fibrinogen, non cross-linked or cross-linked fibrin.  
*Thromb. Res.* 13, 443-451, 1978.
47. Collen D., Rouvier J., Chamone D.A.F., Verstraete M.  
Turnover of radiolabelled plasminogen and prothrombin in cirrhosis of the liver.  
*Eur. J. Clin. Invest.* 8, 185-188, 1978.
48. Collen D., Wiman B.  
Turnover of  $\alpha_2$ -antiplasmin, the fast-acting plasmin inhibitor of plasma.  
*Blood* 53, 313-324, 1979.
49. Wiman B., Lijnen H.R., Collen D.  
On the specific interaction between the lysine binding sites in plasmin and complementary sites in  $\alpha_2$ -antiplasmin and in fibrinogen.  
*Biochim. Biophys. Acta* 579, 142-154, 1979.
50. Cederholm-Williams S.A., De Cock F., Lijnen H.R., Collen D.  
Kinetics of the reactions between streptokinase, plasmin and  $\alpha_2$ -antiplasmin.  
*Eur. J. Biochem.* 100, 125-132, 1979.

51. Wiman B., Collen D.  
On the mechanism of the reaction between human  $\alpha_2$ -antiplasmin and plasmin.  
J. Biol. Chem. 254, 9291-9297, 1979.
52. Plow E.F., De Cock F., Collen D.  
Immunochemical characterization of the plasmin-antiplasmin system. Basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays.  
J. Lab. Clin. Med. 93, 199-209, 1979.
53. Collen D., Verstraete M.  
 $\alpha_2$ -Antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy.  
Thromb. Res. 14, 631-639, 1979.
54. Félez J., Plow E.F., Wiman B., Collen D.  
A coagulo-radioimmunochemical assay for the quantitation of fibrin monomer in human plasma. Principles and development of the method.  
Thromb. Res. 16, 175-189, 1979.
55. Plow E.F., Wiman B., Collen D.  
Changes in antigenic structure and conformation of  $\alpha_2$ -antiplasmin induced by interaction with plasmin.  
J. Biol. Chem. 255, 2902-2906, 1980.
56. Collen D., Lijnen H.R., De Cock F., Durieux J.P., Loffet A.  
Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases.  
Biochim. Biophys. Acta 615, 158-166, 1980.
57. Lijnen H.R., Hoylaerts M., Collen D.  
Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein.  
J. Biol. Chem. 255, 10214-10222, 1980.
58. Rákóczi I., Chamone D., Verstraete M., Collen D.  
The relevance of clinical and hemostasis parameters for the prediction of postoperative thrombosis of the deep veins of the lower extremities in gynecological patients.  
Surg. Gynec. Obstet. 151, 225-231, 1980.
59. Korninger C., Stassen J.M., Collen D.  
Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits.  
Thromb. Haemost. 46, 658-661, 1981.
60. Lijnen H.R., De Cock F., Collen D.  
Turnover of human histidine-rich glycoprotein in healthy subjects and during thrombolytic therapy.  
Thromb. Res. 23, 121-131, 1981.

61. Hoylaerts M., Lijnen H.R., Collen D.  
Studies on the mechanism of the antifibrinolytic action of tranexamic acid.  
Biochim. Biophys. Acta 673, 75-85, 1981.
62. Matsuo O., Rijken D.C., Collen D.  
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.  
Thromb. Haemost. 45, 225-229, 1981.
63. Matsuo O., Rijken D.C., Collen D.  
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.  
Nature 291, 590-591, 1981.
64. Rijken D.C., Collen D.  
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.  
J. Biol. Chem. 256, 7035-7041, 1981.
65. Weimar W., Stibbe J., van Seyen A.J., Billiau A., De Somer P., Collen D.  
Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator.  
Lancet ii, 1018-1020, 1981.
66. Plow E.F., Collen D.  
Immunochemical characterization of a low affinity lysine binding site within plasminogen.  
J. Biol. Chem. 256, 10864-10869, 1981.
67. Korninger C., Collen D.  
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.  
Thromb. Haemost. 46, 561-565, 1981.
68. Korninger C., Collen D.  
Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.  
Thromb. Haemost. 46, 662-665, 1981.
69. Lijnen H.R., Van Hoef B., Collen D.  
On the role of the carbohydrate side chains of human plasminogen in its interaction with  $\alpha_2$ -antiplasmin and fibrin.  
Eur. J. Biochem. 120, 149-154, 1981.
70. Lijnen H.R., Jacobs G., Collen D.  
Histidine-rich glycoprotein in a normal and a clinical population.  
Thromb. Res. 22, 519-523, 1981.

71. Lijnen H.R., Collen D.  
Degradation of the apoprotein A-I polypeptide chain of human high density lipoprotein by human plasmin.  
Thromb. Res. 24, 151-156, 1981.
72. Plow E.F., Collen D.  
The presence and release of  $\alpha_2$ -antiplasmin from human platelets.  
Blood 58, 1069-1074, 1981.
73. Bykowska K., Rijken D.C., Collen D.  
Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.  
Thromb. Haemost. 46, 642-644, 1981.
74. Matsuo O., Collen D., Verstraete M.  
On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921).  
Thromb. Res. 24, 347-358, 1981.
75. Opdenakker G., Weening H., Collen D., Billiau A., De Somer P.  
Messenger RNA for human tissue plasminogen activator.  
Eur. J. Biochem. 121, 269-274, 1982.
76. Korninger C., Matsuo O., Suy R., Stassen J.M., Collen D.  
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.  
J. Clin. Invest. 69, 573-580, 1982.
77. Hoylaerts M., Rijken D.C., Lijnen H.R., Collen D.  
Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.  
J. Biol. Chem. 257, 2912-2919, 1982.
78. Rijken D.C., Hoylaerts M., Collen D.  
Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator.  
J. Biol. Chem. 257, 2920-2925, 1982.
79. Ceustermans R., Hoylaerts M., De Mol M., Collen D.  
Preparation, characterization and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds.  
J. Biol. Chem. 257, 3401-3408, 1982.
80. Collen D., Rijken D.C., Van Damme J., Billiau A.  
Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo.  
Thromb. Haemost. 48, 294-296, 1982.



81. Collen D., Matsuo O., Stassen J.M., Kettner C. Shaw E.  
In vivo studies of a synthetic inhibitor of thrombin.  
J. Lab. Clin. Med. 99, 76-83, 1982.
82. Bykowska K., Levin E.G., Rijken D.C., Loskutoff D.J., Collen D.  
Characterization of a plasminogen activator secreted by cultured bovine aortic endothelial cells.  
Biochim. Biophys. Acta 703, 113-115, 1982.
83. Lijnen H.R., Wiman B., Van Hoef B., Collen D.  
Purification and partial primary structure of cyanogen bromide fragments from human  $\alpha_2$ -antiplasmin.  
Thromb. Res. 27, 83-89, 1982.
84. Lijnen H.R., Maes M., Castel M., Samama M., Collen D.  
Kinetics of the inhibition of plasmin in acidified human plasma.  
Thromb. Haemost. 48, 257-259, 1982.
85. Lijnen H.R., Wiman B., Collen D.  
Partial primary structure of human  $\alpha_2$ -antiplasmin - homology with other plasma protease inhibitors.  
Thromb. Haemost. 48, 311-314, 1982.
86. Pennica D., Holmes W.E., Kohr W.J., Harkins R.N., Vehar G.A., Ward C.A., Bennett W.F., Yelverton E., Seeburg P.H., Heyneker H.L., Goeddel D.V., Collen D.  
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli.  
Nature 301, 214-221, 1983.
87. Rijken D.C., Juhan-Vague I., De Cock F., Collen D.  
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.  
J. Lab. Clin. Med. 101, 274-284, 1983.
88. Rijken D.C., Juhan-Vague I., Collen D.  
Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.  
J. Lab. Clin. Med. 101, 285-294, 1983.
89. Lijnen H.R., Hoylaerts M., Collen D.  
Neutralization of heparin activity by binding to human histidine-rich glycoprotein.  
Thromb. Res. 29, 443-446, 1983.
90. Lijnen H.R., Collen D.  
Turnover of histidine-rich glycoprotein during heparin administration in man.  
Thromb. Res. 30, 671-676, 1983.

91. Collen D., Stassen J.M., Verstraete M.  
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.  
*J. Clin. Invest.* 71, 368-376, 1983.
92. Lijnen H.R., Hoylaerts M., Collen D.  
Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.  
*J. Biol. Chem.* 258, 3803-3808, 1983.
93. Bergmann S.R., Fox K.A.A., Ter-Pogossian M.M., Sobel B.E., Collen D.  
Clot-selective coronary thrombolysis with tissue-type plasminogen activator.  
*Science* 220, 1181-1183, 1983.
94. Lijnen H.R., Van Hoef B., Collen D.  
Interaction of heparin with histidine-rich glycoprotein and with antithrombin III.  
*Thromb. Haemost.* 50, 560-562, 1983.
95. Collen D.  
Mechanisms of inhibition of tissue-type plasminogen activator in blood.  
*Thromb. Haemost.* 50, 678, 1983.
96. Lijnen H.R., Rylatt D.B., Collen D.  
Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor.  
*Biochim. Biophys. Acta* 742, 109-115, 1983.
97. Hoylaerts M., Holmer E., De Mol M., Collen D.  
Covalent complexes between low molecular weight heparin fragments and antithrombin III. Inhibition kinetics and turnover parameters.  
*Thromb. Haemost.* 49, 109-115, 1983.
98. Van de Werf F., Ludbrook P.A., Bergmann S.R., Tiefenbrunn A.J., Fox K.A.A., De Geest H., Verstraete M., Collen D., Sobel B.E.  
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.  
*N. Engl. J. Med.* 310, 609-613, 1984.
99. Van de Werf F., Bergmann S.R., Fox K.A.A., De Geest H., Hoyng C.F., Sobel B.E., Collen D.  
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.  
*Circulation* 69, 605-610, 1984.
100. Juhan-Vague I., Moerman B., De Cock F., Aillaud M.F., Collen D.  
Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.  
*Thromb. Res.* 33, 523-530, 1984.

101. Hoylaerts M., Owen W.G., Collen D.  
Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III.  
*J. Biol. Chem.* 259, 5670-5677, 1984.
102. Juhan-Vague I., Conte-Devolx B., Aillaud M.F., Mendez C., Oliver C., Collen D.  
Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism.  
*Thromb. Res.* 33, 653-659, 1984.
103. Barbui T., Finazzi G., Mussoni L., Riganti M., Donati M.B., Colucci M., Collen D.  
Hereditary dysfunctional protein C (Protein C Bergamo) and thrombosis.  
*Lancet* ii, 819, 1984.
104. Zamarron C., Lijnen H.R., Collen D.  
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.  
*J. Biol. Chem.* 259, 2080-2083, 1984.
105. Sala N., Owen W.G., Collen D.  
A functional assay of protein C in human plasma.  
*Blood* 63, 671-675, 1984.
106. Lijnen H.R., Soria J., Soria C., Collen D., Caen J.P.  
Dysfibrinogenemia (fibrinogen DUSARD) associated with impaired fibrin-enhanced plasminogen activation.  
*Thromb. Haemost.* 51, 108-109, 1984.
107. Lijnen H.R., Van Hoef B., Collen D.  
Histidine-rich glycoprotein modulates the anticoagulant activity of heparin in human plasma.  
*Thromb. Haemost.* 51, 266-268, 1984.
108. Lijnen H.R., Uytterhoeven M., Collen D.  
Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones.  
*Thromb. Res.* 34, 431-437, 1984.
109. Sobel B.E., Geltman E.M., Tiefenbrunn A.J., Jaffe A.S., Spadaro J.J., Ter-Pogossian M.M., Collen D., Ludbrook P.A.  
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.  
*Circulation* 69, 983-990, 1984.
110. Zamarron C., Lijnen H.R., Collen D.  
Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro.  
*Thromb. Res.* 35, 335-345, 1984.

111. Colucci M., Stassen J.M., Collen D.  
Influence of Protein C activation on blood coagulation and fibrinolysis in squirrel monkeys.  
*J. Clin. Invest.* 74, 200-204, 1984.
112. Zamarron C., Lijnen H.R., Van Hoef B., Collen D.  
Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.  
*Thromb. Haemost.* 52, 19-23, 1984.
113. Collen D., De Cock F., Lijnen H.R.  
Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.  
*Thromb. Haemost.* 52, 24-26, 1984.
114. Collen D., Stassen J.M., Blaber M., Winkler M., Verstraete M.  
Biological and thrombolytic properties of proenzyme and active forms of human urokinase. III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.  
*Thromb. Haemost.* 52, 27-30 1984.
115. Lijnen H.R., De Wreede K., Demarsin E., Collen D.  
Biological and thrombolytic properties of proenzyme and active forms of human urokinase. IV. Variability in fibrinolytic response of plasma of several mammalian species.  
*Thromb. Haemost.* 52, 31-33, 1984.
116. Colucci M., Stassen J.M., Salwa J., Collen D.  
Identification of plasminogen activator releasing activity in the neurohypophysis.  
*Brit. J. haematol.* 58, 337-346, 1984.
117. Lijnen H.R., Van Hoef B., Collen D.  
Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase.  
*Eur. J. Biochem.* 144, 541-544, 1984.
118. Collen D., Stassen J.M., Marafino B., Builder S., De Cock F., Ogez J., Tajiri D., Pennica D., Bennett W.F., Salwa J., Hoyng C.F.  
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.  
*J. Pharmacol. Exper. Therap.* 231, 146-152, 1984.
119. Gold H.K., Fallon J.T., Yasuda T., Leinbach R.C., Khaw B.A., Newell J.B., Guerrero J.L., Vislosky F.M., Hoyng C.F., Grossbard E., Collen D.  
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.  
*Circulation* 70, 700-707, 1984.

120. Burroughs J.N., Sangar D.V., Clarke B.E., Rowlands D.J., Billiau A., Collen D.  
Multiple proteases in foot-and-mouth disease virus replication.  
*J. Virol.* 50, 878-883, 1984.
121. Lijnen H.R., Marafino Jr. B.J., Collen D.  
In vitro fibrinolytic activity of recombinant tissue-type plasminogen activator in the plasma of various primate species.  
*Thromb. Haemost.* 52, 308-310, 1984.
122. Juhan-Vague I., Vague P., Poisson C., Aillaud M.F., Mendez C., Collen D.  
Effect of 24 hours of normoglycaemia on tissue-type plasminogen activator plasma levels in insulin dependent diabetes.  
*Thromb. Haemost.* 51, 97-98, 1984.
123. Vehar G.A., Kohr W.J., Bennett W.F., Pennica D., Ward C.A., Harkins R.N., Collen D.  
Characterization studies on human melanoma cell tissue plasminogen activator.  
*Biotechnology* 2, 1051-1057, 1984.
124. Collen D., Topol E.J., Tiefenbrunn A.J., Gold H.K., Weisfeldt M.L., Sobel B.E., Leinbach R.C., Brinker J.A., Ludbrook P.A., Yasuda T., Bulkley B.H., Robison A.K., Hutter A.M., Bell W.R., Spadaro J.J., Khaw B.A., Grossbard E.B.  
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.  
*Circulation* 70, 1012-1017, 1984.
125. Flameng W., Van de Werf F., Vanhaecke J., Verstraete M., Collen D.  
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.  
*J. Clin. Invest.* 75, 84-90, 1985.
126. Colucci M., Paramo J.A., Collen D.  
Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.  
*J. Clin. Invest.* 75, 818-824, 1985.
127. Mattsson C., Hoylaerts M., Holmer E., Uthne T., Collen D.  
Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III.  
*J. Clin. Invest.* 75, 1169-1173, 1985.
128. Collen D., Stump D., Van De Werf F., Jang I.K., Nobuhara M., Lijnen H.R.  
Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.  
*Circulation* 72, 384-388, 1985.
129. Agnelli G., Buchanan M.R., Fernandez F., Boneu B., Van Rijn J., Hirsh J., Collen D.  
A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits.  
*Circulation* 72, 178-182, 1985.

130. Verstraete M., Bernard R., Bory M., Brower R.W., Collen D., de Bono D.P., Erbel R., Huhmann W., Lennane R.J., Lubsen J., Mathey D., Meyer J., Michels H.R., Rutsch W., Scharl M., Schmidt W., Uebis R., von Essen R.  
Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction.  
*Lancet* 1, 842-847, 1985.
131. Lijnen H.R., Zamarron C., Collen D.  
Characterization of the high-affinity interaction between human plasminogen and pro-urokinase.  
*Eur. J. Biochem.* 150, 141-144, 1985.
132. Aillaud M.F., Juhan-Vague I., Alessi M.C., Marecal M., Vinson M.F., Arnaud C., Vague P., Collen D.  
Increased PA-inhibitor levels in the postoperative period. No cause effect relation with increased cortisol.  
*Thromb. Haemost.* 54, 466-468, 1985.
133. Paramo J.A., Colucci M., Collen D., Van de Werf F.  
Plasminogen activator inhibitor in the blood of patients with coronary artery disease.  
*Brit. Med. J.* 291, 573-574, 1985.
134. Bounameaux H., Vermynen J., Collen D.  
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism.  
*Ann. Int. Med.* 103, 64-65, 1985.
135. Holvoet P., Lijnen H.R., Collen D.  
A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo.  
*J. Biol. Chem.* 260, 12106-12111, 1985.
136. Holvoet P., Cleemput H., Collen D.  
Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.  
*Thromb. Haemost.* 54, 684-687, 1985.
137. Verstraete M., Bounameaux H., De Cock F., Van de Werf F., Collen D.  
Pharmacokinetics and systemic fibrinolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans.  
*J. Pharmacol. Exper. Therap.* 235, 506-512, 1985.
138. Paramo J.A., de Boer A., Colucci M., Jonker J.J.C., Collen D.  
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.  
*Thromb. Haemost.* 54, 725, 1985.

139. Lijnen H.R., Van Hoef B., Wiman B., Collen D.  
Modification of a tyrosine residue in the carboxyterminal portion of human  $\alpha_2$ -antiplasmin.  
Thromb. Res. 39, 625-629, 1985.
140. Verstraete M., Bleifeld W., Brower R.W., Charbonnier B., Collen D., de Bono D.P., Dunning A.J., Lennane R.J., Lubsen J., Mathey D.G., Michel P.L., Raynaud Ph., Schofer J., Vahanian A., Vanhaecke J., van de Kley G.A., Van de Werf F., von Essen R.  
Double-blind, randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.  
Lancet 2, 965-969, 1985.
141. Bounameaux H., Gresele P., Hanss M., De Cock F., Vermynen J., Collen D.  
Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion.  
Thromb. Res. 40, 161-170, 1985.
142. Collen D., Bounameaux H., De Cock F., Lijnen H.R., Verstraete M.  
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.  
Circulation 73, 511-517, 1986.
143. Vague P., Juhan-Vague I., Aillaud M.F., Badier C., Viard R., Alessi M.C., Collen D.  
Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects.  
Metabolism 35, 250-253, 1986.
144. Lijnen H.R., Zamarron C., Blaber M., Winkler M.E., Collen D.  
Activation of plasminogen by pro-urokinase. I. Mechanism.  
J. Biol. Chem. 261, 1253-1258, 1986.
145. Collen D., Zamarron C., Lijnen H.R., Hoylaerts M.  
Activation of plasminogen by pro-urokinase. II. Kinetics.  
J. Biol. Chem. 261, 1259-1266, 1986.
146. Stump D.C., Thienpont M., Collen D.  
Urokinase-related proteins in human urine. Isolation and characterization of single chain urokinase (pro-urokinase) and urokinase-inhibitor complex.  
J. Biol. Chem. 261, 1267-1273, 1986.
147. Stump D.C., Lijnen H.R., Collen D.  
Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures.  
J. Biol. Chem. 261, 1274-1278, 1986.

148. Gold H.K., Leinbach R.C., Garabedian H.D., Yasuda T., Johns J.A., Grossbard E.B., Palacios I., Collen D.  
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.  
*Circulation* 73, 347-352, 1986.
149. Van de Werf F., Nobuhara M., Collen D.  
Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.  
*Ann. Int. Med.* 104, 345-348, 1986.
150. Flameng W., Vanhaecke J., Stump D.C, Van de Werf F., Holmes W., Guenzler W.A., Flohé L., Collen D.  
Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: Effect on regional blood flow, infarct size and hemostasis.  
*J. Am. Coll. Cardiol.* 8, 118-124, 1986.
151. Bounameaux H., Stassen J.M., Seghers C., Collen D.  
Influence of fibrin and liver blood flow on the turnover and the systemic fibrinolytic effects of recombinant human tissue-type plasminogen activator in rabbits.  
*Blood* 67, 1493-1497, 1986.
152. Holvoet P., Lijnen H.R., Collen D.  
A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin : useful to monitor fibrinogen breakdown during t-PA infusion.  
*Blood* 67, 1482-1487, 1986.
153. Holvoet P., Lijnen H.R., Collen D.  
A monoclonal antibody directed against the high-affinity lysine-binding site (LBS) of human plasminogen. Role of LBS in the regulation of fibrinolysis.  
*Eur. J. Biochem.* 157, 65-69, 1986.
154. Colucci M., Paramo J.A., Collen D.  
Inhibition of one-chain and two-chain forms of human tissue-type plasminogen activator (t-PA) by the fast-acting inhibitor of plasminogen activator (PA-inhibitor) in vitro and in vivo.  
*J. Lab. Clin. Med.* 108, 53-59, 1986.
155. Verstraete M., Su C.A.P.F., Tanswell P., Feuerer W., Collen D.  
Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.  
*Thromb. Haemost.* 56, 1-5, 1986.
156. Garabedian H., Gold H.K., Leinbach R.C., Yasuda T., Johns J.A., Collen D.  
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.  
*Am. J. Cardiol.* 58, 673-679, 1986.



157. Lijnen H.R., Collen D.  
Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator.  
*Thromb. Res.* 43, 687-690, 1986.
158. Holvoet P., de Boer A., Verstreken M., Collen D.  
An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin- $\alpha_2$ -antiplasmin complex in human plasma. Application to the detection of in vivo activation of the fibrinolytic system.  
*Thromb. Haemost.* 56, 124-127, 1986.
159. Lijnen H.R., Van Hoef B., Collen D.  
Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.  
*Biochim. Biophys. Acta* 884, 402-408, 1986.
160. Jang I.K., Vanhaecke J., De Geest H., Verstraete M., Collen D., Van de Werf F.  
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.  
*J. Am. Coll. Cardiol.* 8, 1455-1460, 1986.
161. Darras V., Thienpont M., Stump D.C., Collen D.  
Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies.  
*Thromb. Haemost.* 56, 411-414, 1986.
162. Colucci M., Paramo J.A., Stassen J.M., Collen D.  
Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.  
*J. Clin. Invest.* 78, 138-144, 1986.
163. Holvoet P., Lijnen H.R., Collen D.  
Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies.  
*Eur. J. Biochem.* 158, 173-177, 1986.
164. Collen D., De Cock F., Demarsin E., Lijnen H.R., Stump D.C.  
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.  
*Thromb. Haemost.* 56, 35-39, 1986.
165. Stump D.C., Thienpont M., Collen D.  
Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma.  
*J. Biol. Chem.* 261, 12759-12766, 1986.

166. Collen D., Stassen J.M., Stump D.C., Verstraete M.  
Synergism of thrombolytic agents in vivo.  
*Circulation* 74, 838-842, 1986.
167. Van de Werf F., Vanhaecke J., De Geest H., Verstraete M., Collen D.  
Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.  
*Circulation* 74, 1066-1070, 1986.
168. Collen D., Stump D.C., Van de Werf F.  
Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents.  
*Am. Heart J.* 112, 1083-1084, 1986.
169. Stump D.C., Lijnen H.R., Collen D.  
Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.  
*J. Biol. Chem.* 261, 17120-17126, 1986.
170. Hanss M., Collen D.  
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine.  
*J. Lab. Clin. Med.* 109, 97-104, 1987.
171. Van de Werf F., Jang I.K., Collen D.  
Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA). Dose-response in dogs with coronary artery thrombosis.  
*J. Cardiovasc. Pharmacol.* 9, 91-93, 1987.
172. Lijnen H.R., Van Hoef B., Collen D.  
Differential reactivity of Glu-Gly-Arg-CH<sub>2</sub>Cl, a synthetic urokinase inhibitor, with single-chain or two-chain forms of urokinase-type plasminogen activator.  
*Eur. J. Biochem.* 162, 351-356, 1987.
173. Stump D.C., Stassen J.M., Demarsin E., Collen D.  
Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.  
*Blood* 69, 592-596, 1987.
174. Juhan-Vague I., Valadier J., Alessi M.C., Aillaud M.F., Ansaldi J., Philip-Joet C., Holvoet P., Serradimigni A., Collen D.  
Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.  
*Thromb. Haemost.* 57, 67-72, 1987

175. Holvoet P., Boes J., Collen D.  
Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody.  
*Blood* 69, 284-289, 1987.
176. Holmes W.E., Nelles L., Lijnen H.R., Collen D.  
Primary structure of human  $\alpha_2$ -antiplasmin, a serine protease inhibitor (serpin).  
*J. Biol. Chem.* 262, 1659-1664, 1987
177. Garabedian H.D., Gold H.K., Leinbach R.C., Johns J.A., Yasuda T., Kanke M., Collen D.  
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.  
*J. Am. Coll. Cardiol.* 9, 599-607, 1987.
178. Van de Werf F., Vanhaecke J., Jang I.K., Flameng W., Collen D., De Geest H.  
Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol.  
*Circulation* 75, 830-836, 1987.
179. Gold H.K., Johns J.A., Leinbach R.C., Yasuda T., Grossbard E., Zusman R., Collen D.  
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.  
*Circulation* 75, 1192-1199, 1987.
180. Nelles L., Lijnen H.R., Collen D., Holmes W.E.  
Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.  
*J. Biol. Chem.* 262, 5682-5689, 1987.
181. Nelles L., Lijnen H.R., Collen D., Holmes W.E.  
Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.  
*J. Biol. Chem.* 262, 10855-10862, 1987.
182. Topol E.J., Morris D.C., Smalling R.W., Schumacher R.R., Taylor C.R., Nishikawa A., Liberman H.A., Collen D., Tufte M.E., Grossbard E.B., O'Neill W.W.  
A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.  
*J. Am. Coll. Cardiol.* 9, 1205-1213, 1987.
183. Stump D.C., Kieckens L., De Cock F., Collen D.  
Pharmacokinetics of single-chain forms of urokinase-type plasminogen activator.  
*J. Pharmacol. Exper. Therap.* 242, 245-250, 1987.

184. Lijnen H.R., Holmes W.E., Van Hoef B., Wiman B., Rodriguez H., Collen D.  
Amino-acid sequence of human  $\alpha_2$ -antiplasmin.  
Eur. J. Biochem. 166, 565-574, 1987.
185. Piérard L., Jacobs P., Gheysen D., Hoylaerts M., André B., Topisirovic L., Cravador A., de Foresta F., Herzog A., Collen D., De Wilde M., Bollen A.  
Mutant and chimeric recombinant plasminogen activators : Production in eukaryotic cells and preliminary characterization.  
J. Biol. Chem. 262, 11771-11778, 1987.
186. Gheysen D., Lijnen H.R., Piérard L., de Foresta F., Demarsin E., Jacobs P., De Wilde M., Bollen A., Collen D.  
Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.  
J. Biol. Chem. 262, 11779-11784, 1987.
187. Verstraete M., Arnold A.E.R., Brower R.W., Collen D., de Bono D.P., de Zwaan C., Erbel R., Hillis W.S., Lennane R.J., Lubsen J., Mathey D., Reid D.S., Rutsch W., Scharl M., Schofer J., Serruys P.W., Simoons M.L., Uebis R., Vahanian A., Verheugt F.W.A., von Essen R.  
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.  
Am. J. Cardiol. 60, 231-237, 1987.
188. Holmes W.E., Lijnen H.R., Collen D.  
Characterization of recombinant human  $\alpha_2$ -antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site.  
Biochemistry 26, 5133-5140, 1987
189. Collen D., Van de Werf F.  
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.  
Am. J. Cardiol. 60, 431-434, 1987.
190. Holmes W.E., Lijnen H.R., Nelles L., Kluft C., Nieuwenhuis H.K., Rijken D.C., Collen D.  
 $\alpha_2$ -Antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity.  
Science 238, 209-211, 1987.
191. Cambier P., Mombaerts P., De Geest H., Collen D., Van de Werf F.  
Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator.  
Eur. Heart J. 8, 906-909, 1987.

192. Collen D., Stassen J.M., De Cock F.  
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.  
Thromb. Haemost. 58, 943-946, 1987.
193. Stassen J.M., Juhan-Vague I., Alessi M.C., De Cock F., Collen D.  
Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.  
Thromb. Haemost. 58, 947-950, 1987.
194. Lijnen H.R., Van Hoef B., Collen D.  
Activation with plasmin of two-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.  
Eur. J. Biochem. 169, 359-364, 1987.
195. Heeb M.J., España F., Geiger M., Collen D., Stump D.C., Griffin J.H.  
Immunological identity of heparin-dependent plasma and urinary Protein C inhibitor and plasminogen activator inhibitor-3.  
J. Biol. Chem. 262, 15813-15816, 1987.
196. Declerck P.J., Mombaerts P., Holvoet P., De Mol M., Collen D.  
Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.  
Thromb. Haemost. 58, 1024-1029, 1987.
197. Ballegeer V., Mombaerts P., Declerck P.J., Spitz B., Van Assche F.A., Collen D.  
Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy.  
Thromb. Haemost. 58, 1030-1032, 1987.
198. Paulusma-de Waal J.H., de Boer A.C., Cox P.H., Stassen J.M., Collen D., Pillay M.  
Technetium labeled plasminogen activator - a potential reagent for thrombus detection.  
Nuc. Compact. 18, 284-286, 1987.
199. Collen D., Stassen J.M., Larsen G.  
Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.  
Blood 71, 216-219, 1988.
200. Declerck P.J., Alessi M.C., Verstreken M., Kruithof E.K.O., Juhan-Vague I., Collen D.  
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.  
Blood 71, 220-225, 1988.

201. Gold H.K., Collier B.S., Yasuda T., Saito T., Fallon J.T., Guerrero J.L., Leinbach R.C., Ziskind A.A., Collen D.  
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.  
*Circulation* 77, 670-677, 1988.
202. Garabedian H.D., Gold H.K., Yasuda T., Johns J.A., Finkelstein D.M., Gaivin R.J., Cobbaert C., Leinbach R.C., Collen D.  
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.  
*J. Am. Coll. Cardiol.* 11, 729-734, 1988.
203. Lijnen H.R., Nelles L., Holmes W.E., Collen D.  
Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.  
*J. Biol. Chem.* 263, 5594-5598, 1988.
204. Cambier P., Van de Werf F., Larsen G.R., Collen D.  
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.  
*J. Cardiovasc. Pharmacol.* 11, 468-472, 1988.
205. Johns J.A., Gold H.K., Leinbach R.C., Yasuda T., Gimple L.W., Werner W., Finkelstein D.B., Newell J.B., Ziskind A.A., Collen D.  
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction: a randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.  
*Circulation* 78, 546-556, 1988.
206. Declerck P.J., De Mol M., Alessi M.C., Baudner S., Pâques E.P., Preissner K.T., Müller-Berghaus G., Collen D.  
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).  
*J. Biol. Chem.* 263, 15454-15461, 1988.
207. Alessi M.C., Juhan-Vague I., Kooistra T., Declerck P.J., Collen D.  
Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2.  
*Thromb. Haemost.* 60, 491-494, 1988.
208. Lijnen H.R., Van Hoef B., Nelles L., Holmes W.E., Collen D.  
Enzymatic properties of single-chain and two-chain forms of a Lys158 -> Glu158 mutant of urokinase-type plasminogen activator.  
*Eur. J. Biochem.* 172, 185-188, 1988.

209. Lijnen H.R., Gheysen D., de Foresta F., Piérard L., Jacobs P., Bollen A., Collen D.  
Characterization of a mutant of recombinant human single chain urokinase-type plasminogen activator (scu-PA) obtained by substitution of Arginine 156 and Lysine 158 with Threonine.  
*Fibrinolysis* 2, 85-93, 1988.
210. Auwerx J., Bouillon R., Collen D., Geboers J.  
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.  
*Arteriosclerosis* 8, 68-72, 1988.
211. Stump D.C., Topol E.J., Chen A.B., Hopkins A., Collen D.  
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.  
*Thromb. Haemost.* 59, 133-137, 1988.
212. Alessi M.C., Juhan-Vague I., Valadier J., Philip-Joet C., Holvoet P., Collen D.  
Relevance of free t-PA assay following venous occlusion in patients with venous thromboembolic disease.  
*Thromb. Haemost.* 59, 346-347, 1988.
213. Yasuda T., Gold H.K., Fallon J.T., Leinbach R.C., Guerrero J.L., Scudder L.E., Kanke M., Shealy D., Ross M., Collen D., Collier B.S.  
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.  
*J. Clin. Invest.* 81, 1284-1291, 1988.
214. Topol E.J., Califf R.M., George B.S., Kereiakes D.J., Rothbaum D., Candela R.J., Abbottsmith C.W., Pinkerton C.A., Stump D.C., Collen D., Lee K.L., Pitt B., Kline E.M., Boswick J.M., O'Neill W.W., Stack R.S.  
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in acute myocardial infarction.  
*Circulation* 77, 1100-1107, 1988.
215. Garabedian H.D., Gold H.K., Leinbach R.C., Yasuda T., Johns J.A., Thornton D., Collen D.  
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.  
*Thromb. Res.* 50, 121-133, 1988.
216. Alessi M.C., Declerck P.J., De Mol M., Nelles L., Collen D.  
Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).  
*Eur. J. Biochem.* 175, 531-540, 1988.

217. Miles L.A., Levin E.G., Plescia J., Collen D., Plow E.F.  
Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells.  
*Blood* 72, 628-635, 1988.
218. Hansen L., Blue Y., Barone K., Collen D., Larsen G.R.  
Functional effects of asparagine-linked oligosaccharide on natural and variant human tissue-type plasminogen activator.  
*J. Biol. Chem.* 263, 15713-15719, 1988.
219. Lijnen H.R., Nelles L., Van Hoef B., De Cock F., Collen D.  
Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH<sub>2</sub>-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.  
*Thromb. Haemost.* 60, 247-250, 1988.
220. Lijnen H.R., Nelles L., Van Hoef B., Demarsin E., Collen D.  
Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.  
*J. Biol. Chem.* 263, 19083-19091, 1988.
221. Lijnen H.R., Nelles L., Van Hoef B., Demarsin E., Collen D.  
Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.  
*Eur. J. Biochem.* 177, 575-582, 1988.
222. Spriggs D., Gold H.K., Hashimoto Y., Van Houtte E., Vermeylen J., Collen D.  
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.  
*Thromb. Haemost.* 61, 93-96, 1989.
223. Spriggs D.J., Stassen J.M., Hashimoto Y., Collen D.  
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.  
*Blood* 73, 1207-1212, 1989.
224. Holvoet P., Stassen J.M., Hashimoto Y., Spriggs D., Devos P., Collen D.  
Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits.  
*Thromb. Haemost.* 61, 307-313, 1989.



225. Collen D., Mao J., Stassen J.M., Broeze R., Lijnen H.R., Abercrombie D., Puma P., Almeda S., Vovis G.F.  
Thrombolytic properties of Lys-158 mutants of recombinant single chain urokinase-type plasminogen activator (scu-PA) in rabbits with jugular vein thrombosis.  
*J. Vasc. Med. Biol.* 1, 46-49, 1989.
226. Collen D., Stassen J.M., Demarsin E., Kieckens L., Lijnen H.R., Nelles L.  
Pharmacokinetics and thrombolytic properties of chimaeric plasminogen activators consisting of the NH<sub>2</sub>-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator.  
*J. Vasc. Med. Biol.* 1, 234-240, 1989.
227. Ziskind A.A., Gold H.K., Yasuda T., Kanke M., Guerrero J.L., Fallon J.T., Saito T., Collen D.  
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high grade stenosis.  
*Circulation* 79, 393-399, 1989.
228. Hashimoto Y., Stassen J.M., Leclef B., De Roo M., Vandecruys A., Melin J., Verhoeven-Mester D., Trouet A., Collen D.  
Thrombus imaging with <sup>123</sup>I-labeled F(ab')<sub>2</sub> fragment of an anti-human fibrin monoclonal antibody in a rabbit model.  
*Radiology* 171, 223-226, 1989.
229. Jang I.K., Gold H.K., Ziskind A.A., Fallon J.T., Holt R.E., Leinbach R.C., May J.W., Collen D.  
Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator (rt-PA). A possible explanation for resistance to coronary thrombolysis.  
*Circulation* 79, 920-928, 1989.
230. Lijnen H.R., Van Hoef B., De Cock F., Collen D.  
The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.  
*Blood* 73, 1864-1872, 1989.
231. Yasuda T., Gold H.K., Fallon J.T., Leinbach R.C., Garabedian H.D., Guerrero J.L., Collen D.  
A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.  
*J. Am. Coll. Cardiol.* 13, 1409-1414, 1989.
232. Juhan-Vague I., Alessi M.C., Joly P., Thirion X., Vague P., Declerck P.J., Serradimigni A., Collen D.  
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.  
*Arteriosclerosis* 9, 362-367, 1989.

233. Vaughan D.E., Declerck P.J., De Mol M., Collen D.  
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with combined administration of tissue-type plasminogen activator and aspirin in rabbits.  
*J. Clin. Invest.* 84, 586-591, 1989.
234. Vaughan D.E., Mendelsohn M.E., Declerck P.J., Van Houtte E., Collen D., Loscalzo J.  
Characterization of the binding of human tissue-type plasminogen activator to platelets.  
*J. Biol. Chem.* 264, 15869-15874, 1989.
235. Ballegeer V., Spitz B., Kieckens L., Moreau H., Van Assche A., Collen D.  
Predictive value of increased plasma levels of fibronectin in gestational hypertension.  
*Am. J. Obstet. Gynecol.* 161, 432-436, 1989.
236. Dewerchin M., Lijnen H.R., Van Hoef B., De Cock F., Collen D.  
Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.  
*Eur. J. Biochem.* 185, 141-149, 1989.
237. Arnold A.E.R., Brower R.W., Collen D., Van Es G.A., Lubsen J., Serruys P.W., Simoons M.L., Verstraete M.  
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency.  
*J. Am. Coll. Cardiol.* 14, 581-588, 1989.
238. Collen D., Dewerchin M., Stassen J.M., Kieckens L., Lijnen H.R.  
Thrombolytic and pharmacokinetic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.  
*Fibrinolysis* 3, 197-202, 1989.
239. Sabovic M., Lijnen H.R., Keber D., Collen D.  
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.  
*Thromb. Haemost.* 62, 1083-1087, 1989.
240. Gimple L.W., Gold H.K., Leinbach R.C., Coller B.S., Werner W., Yasuda T., Johns J.A., Ziskind A.A., Finkelstein D., Collen D.  
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.  
*Circulation* 80, 581-588, 1989.

241. Stump D.C., Califf R.M., Topol E., Sigmon K., Thornton D., Masek R., Anderson L., Collen D.  
Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction.  
*Circulation* 80, 1222-1230, 1989.
242. Russell M.E., Quertermous T., Declerck P.J., Collen D., Haber E., Homcy C.J.  
Binding of tissue-type plasminogen activator with human endothelial cell monolayers. Characterization of the high affinity interaction with plasminogen activator inhibitor-1.  
*J. Biol. Chem.* 265, 2569-2575, 1990.
243. Lijnen H.R., Van Hoef B., Nelles L., Collen D.  
Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser 740 -> Ala) and plasmin-resistant scu-PA (Lys 158 -> Glu).  
*J. Biol. Chem.* 265, 5232-5236, 1990.
244. Dewerchin M., Lijnen H.R., Collen D.  
Characterization of a chemical conjugate between a low molecular weight form of recombinant single chain urokinase-type plasminogen activator (comprising Leu144 through Leu411) and f(ab)<sub>2</sub> fragments of a fibrin D-dimer specific monoclonal antibody.  
*Fibrinolysis* 4, 11-18, 1990.
245. Dewerchin M., Lijnen H.R., Van Hoef B., De Cock F., Collen D.  
Characterization of conjugates of thrombin-treated single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.  
*Fibrinolysis* 4, 19-26, 1990.
246. Lijnen H.R., Dewerchin M., De Cock F., Collen D.  
Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.  
*Thromb. Res.* 57, 333-342, 1990.
247. Stassen J.M., Vanlinthout I., Lijnen H.R., Collen D.  
A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents.  
*Fibrinolysis* 4, 15-21, 1990.
248. Vaughan D., Van Houtte E., Collen D.  
Urokinase binds to platelets through a specific saturable and low affinity mechanism.  
*Fibrinolysis* 4, 141-146, 1990.
249. Wu Z., Van de Werf F., Stassen T., Mattsson C., Pohl G., Collen D.  
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like and first kringle domains (amino acids 6-173), in a canine model.  
*J. Cardiovasc. Pharmacol.* 16, 197-203, 1990.

250. Nelles L., Lijnen H.R., Van Nuffelen A., Demarsin E., Collen D.  
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).  
Thromb. Haemost. 64, 53-60, 1990.
251. Lijnen H.R., Van Hoef B., De Cock F., Collen D.  
Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA). Studies with active site mutagenized plasminogen and plasmin resistant t-PA.  
Thromb. Haemost. 64, 61-68, 1990.
252. Jang I.-K., Gold H.K., Ziskind A.A., Leinbach R.C., Fallon J.T., Collen D.  
Prevention of platelet-mediated arterial thrombosis by selective thrombin inhibition.  
Circulation 81, 219-225, 1990.
253. Declerck P.J., Lijnen H.R., Verstreken M., Moreau H., Collen D.  
A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.  
Blood 75, 1794-1800, 1990.
254. Lijnen H.R., Nelles L., Van Hoef B., De Cock F., Collen D.  
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.  
J. Biol. Chem. 265, 5677-5683, 1990.
255. Collen D., Lijnen H.R., Bulens F., Vandamme A., Tulinsky A., Nelles L.  
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.  
J. Biol. Chem. 265, 12184-12191, 1990.
256. Gold H.K., Gimple L.W., Yasuda T., Leinbach R.C., Werner W., Holt R., Jordan R., Berger H., Collen D., Coller B.S.  
Pharmacodynamic study of F(ab')<sub>2</sub> fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.  
J. Clin. Invest. 86, 651-659, 1990.
257. Yasuda T., Gold H.K., Yaoita H., Leinbach R.C., Guerrero J.L., Jang I.K., Holt R., Fallon J.T., Collen D.  
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet GPIIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.  
J. Am. Coll. Cardiol. 16, 714-722, 1990.

258. Vandamme A.M., Bulens F., Bernar H., Nelles L., Lijnen H.R., Collen D.  
Construction and characterization of a recombinant murine monoclonal antibody directed against human fibrin fragment D-dimer.  
*Eur. J. Biochem.* 192, 767-775, 1990.
259. Collen D., Dewerchin M., Rapold H.J., Lijnen H.R., Stassen J.M.  
Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.  
*Circulation* 82, 1744-1753, 1990.
260. Vaughan D.E., Declerck P.J., Van Houtte E., De Mol M., Collen D.  
Studies of recombinant plasminogen activator inhibitor-1 in rabbits: pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo.  
*Circ. Res.* 67, 1281-1286, 1990.
261. Lijnen H.R., Nelles L., Van Houtte E., Collen D.  
Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator (scu-PA) obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.  
*Fibrinolysis* 4, 211-214, 1990.
262. Lawler C.W., Bovill E.G., Stump D.C., Collen D., Mann K.G., Tracy R.P.  
Fibrin fragment D-dimer and fibrinogen B $\beta$  peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.  
*Blood* 76, 1341-1348, 1990.
263. Eisenberg P.R., Jaffe A.S., Stump D.C., Collen D., Bovill E.G.  
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.  
*Circulation* 82, 1159-1168, 1990.
264. Rapold H.J., Wu Z., Stassen T., Van de Werf F., Collen D.  
Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.  
*Blood* 76, 1558-1563, 1990.
265. Preissner K.T., Grulich-Henn J., Ehrlich H.J., Declerck P., Justus C., Collen D., Pannekoek H., Müller-Berghaus G.  
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.  
*J. Biol. Chem.* 265, 18490-18498, 1990.
266. Sabovic M., Lijnen H.R., Keber D., Collen D.  
Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis.  
*Thromb. Haemost.* 64, 450-454, 1990.

267. Alessi M.C., Juhan-Vague I., Declerck P.J., Anfosso F., Gueunoun E., Collen D. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. *Thromb. Res.* 60, 509-516, 1990.
268. Shatos M.A., Doherty J.M., Stump D.C., Thompson A., Collen D. Oxygen radicals generated during anoxia followed by reoxygenation reduce the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cell culture. *J. Biol. Chem.* 265, 20443-20448, 1990.
269. Jang I.K., Gold H.K., Leinbach R.C., Fallon J.T., Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. *Circ. Res.* 67, 1552-1561, 1990.
270. Yasuda T., Gold H.K., Leinbach R.C., Saito T., Guerrero J.L., Jang I.-K., Holt R., Fallon J.T., Collen D. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and anti-platelet GPIIb/IIIa antibody. *J. Am. Coll. Cardiol.* 16, 1728-1735, 1990.
271. Bartha K., Declerck P.J., Moreau H., Nelles L., Collen D. Synthesis and secretion of plasminogen activator inhibitor 1 by human endothelial cells in vitro. Effect of active site mutagenized tissue-type plasminogen activator. *J. Biol. Chem.* 266, 792-797, 1991.
272. Bulens F., Vandamme A.-M., Bernar H., Nelles L., Lijnen H.R., Collen D. Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment D-dimer. *Eur. J. Biochem.* 195, 235-242, 1991.
273. Yasuda T., Gold H.K., Leinbach R.C., Yaoita H., Fallon J.T., Guerrero L., Napier M.A., Bunting S., Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. *Circulation* 83, 1038-1047, 1991.
274. Garabedian H.D., Gold H.K., Leinbach R.C., Svizzero T.A., Finkelstein D.M., Guerrero J.L., Collen D. Bleeding-time prolongation and bleeding during infusion of recombinant tissue-type plasminogen-activator in dogs - potentiation by aspirin and reversal with aprotinin. *J. Am. Coll. Cardiol.* 17, 1213-1222, 1991.
275. Lijnen H.R., Van Hoef B., De Cock F., Okada K., Ueshima S., Matsuo O., Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. *J. Biol. Chem.* 266, 11826-11832, 1991.

276. Collen D., Lijnen H.R., Vanlinthout I., Kieckens L., Nelles L., Stassen J.M.  
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.  
*Thromb. Haemost.* 65, 174-180, 1991.
277. Gore J.M., Sloan M., Price T.R., Randall A.M.Y., Bovill E., Collen D., Forman S., Knatterud G.L., Sopko G., Terrin M.L.  
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in myocardial infarction study, phase II, pilot and clinical trial.  
*Circulation* 83, 448-459, 1991.
278. Sane D.C., Stump D.C., Topol E.J., Sigmon K.N., Kereiakes D.J., George B.S., Mantell S.J., Macy E., Collen D., Califf R.M.  
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.  
*Thromb. Haemost.* 65, 275-279, 1991.
279. Philippé J., Offner F., Declerck P.J., Leroux-Roels G., Vogelaers D., Baele G., Collen D.  
Fibrinolysis and coagulation in patients with infectious disease and sepsis.  
*Thromb. Haemost.* 65, 291-295, 1991.
280. Lijnen H.R., Van Hoef B., Collen D.  
On the reversible interaction of plasminogen activator inhibitor-1 with tissue-type plasminogen activator and with urokinase-type plasminogen activator.  
*J. Biol. Chem.* 266, 4041-4044, 1991.
281. Rapold H.J., Lu H.R., Wu Z., Nijs H., Collen D.  
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.  
*Blood* 77, 1020-1024, 1991.
282. Declerck P.J., Lijnen H.R., Verstreken M., Collen D.  
Role of  $\alpha_2$ -antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.  
*Thromb. Haemost.* 65, 394-398, 1991.
283. Rapold H.J., Van de Werf F., De Geest H., Arnout J., Sangtawesin W., Vercammen E., De Clerck F., Weber C., Collen D.  
Pilot study of combined administration of ridogrel and alteplase in patients with acute myocardial infarction.  
*Coron. Art. Dis.* 2, 455-463, 1991.

284. Laroche Y., Demaeyer M., Stassen J.M., Gansemans Y., Demarsin E., Matthyssens G., Collen D., Holvoet P.  
Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer.  
*J. Biol. Chem.* 266, 16343-16349, 1991.
285. Vaughan D.E., Van Houtte E., Declerck P.J., Collen D.  
Streptokinase-induced platelet aggregation: prevalence and mechanism.  
*Circulation* 84, 84-91, 1991.
286. Collen D., Lu H.R., Lijnen H.R., Nelles L., Stassen J.M.  
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.  
*Circulation* 84, 1216-1234, 1991.
287. Holvoet P., Laroche Y., Lijnen H.R., Van Cauwenberge R., Demarsin E., Brouwers E., Matthyssens G., Collen D.  
Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.  
*J. Biol. Chem.* 266, 19717-19724, 1991.
288. Thompson E.A., Nelles L., Collen D.  
Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells.  
*Eur. J. Biochem.* 201, 627-632, 1991.
289. Alessi M.C., Juhan-Vague I., Declerck P.J., Collen D.  
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma.  
*Thromb. Res.* 62, 275-285, 1991.
290. Stassen J.M., Lijnen H.R., Vanlinthout I., Collen D.  
Thrombolysis with bolus injections and infusions of tissue-type plasminogen activator in rabbits with experimental jugular vein thrombosis.  
*Fibrinolysis* 5, 165-170, 1991.
291. Lu H.R., Lijnen H.R., Stassen J.M., Collen D.  
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.  
*Blood* 78, 125-131, 1991.
292. Dewerchin M., Lijnen H.R., Stassen J.M., De Cock F., Quertermous T., Ginsburg M., Plow E.F., Collen D.  
Effect of chemical conjugation of recombinant single chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.  
*Blood* 78, 1005-1018, 1991.



293. Bovill E., Terrin M., Stump D.C., Berke A., Frederick M., Collen D., Feit F., Gore J.M., Hillis L.D., Lambrew C.T., Leiboff R., Mann K.G., Markis J.E., Pratt C.M., Sharkey S.W., Sopko G., Tracy R.R., Chesebro J.H.  
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) Phase II trial.  
*Ann. Int. Med.* 115, 256-265, 1991.
294. Lijnen H.R., Stassen J.M., Vanlinthout I., Fukao H., Okada K., Matsuo O., Collen D.  
Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis.  
*Thromb. Haemost.* 66, 468-473, 1991.
295. Kurokawa T., Iwasa S., Kakinuma A., Stassen J.M., Lijnen H.R., Collen D.  
Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.  
*Thromb. Haemost.* 66, 684-693, 1991.
296. Lu H.R., Gold H.K., Wu Z., De Cock F., Jang I.K., Pauwels P., Collen D.  
Acceleration and persistence of recombinant tissue plasminogen activator induced arterial eversion graft recanalization with a single bolus injection of F(ab')<sub>2</sub> fragments of the antiplatelet GPIIb/IIIa antibody 7E3.  
*Coron. Art. Dis.* 2, 1039-1046, 1991.
297. Yasuda T., Gold H.K., Yaotia H., Guerrero J.L., Holt R.E., Fallon J.T., Holt R.E., Fallon J.T., Leinbach R.C., Collen D.  
Antithrombotic effects of ridogrel, a combined thromboxane A<sub>2</sub> synthase inhibitor and prostaglandin endoperoxide-receptor antagonist, in a platelet-mediated coronary artery occlusion preparation in the dog.  
*Coron. Art. Dis.* 2, 1103-1110, 1991.
298. Collen D., Masuda M., Lu H.R., Flameng W., Verheyen A., De Clerck F., Gold H.K.  
Effect of ridogrel, a combined thromboxane A<sub>2</sub> synthase inhibitor/prostaglandin endoperoxide receptor antagonist, on the lysis of platelet-rich coronary arterial thrombi with recombinant tissue-type plasminogen activator in a canine model.  
*Fibrinolysis* 6, 7-15, 1992.
299. Lijnen H.R., De Cock F., Matsuo O., Collen D.  
Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro.  
*Fibrinolysis* 6, 33-37, 1992.
300. Shatos M.A., Doherty J.M., Orfeo T., Hoak J.C., Collen D., Stump D.C.  
Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals.  
*J. Biol. Chem.* 267, 597-601, 1992.

301. Rapold H.J., De Bono D., Arnold A.E.R., Arnout J., De Cock F., Collen D., Verstraete M. for the European Cooperative Study Group.  
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia.  
*Circulation* 85, 928-934, 1992.
302. Vandamme A.M., Dewerchin M., Lijnen H.R., Bernar H., Bulens F., Nelles L., Collen D.  
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.  
*Eur. J. Biochem.* 205, 139-146, 1992.
303. Bulens F., Nelles L., Van den Panhuyzen N., Collen D.  
Stimulation by retinoids of tissue-type plasminogen activator secretion in cultured human endothelial cells - Relations of structure to effect.  
*J. Cardiovasc. Pharmacol.* 19, 508-514, 1992.
304. Rapold H.J., Stassen T., Van de Werf F., Collen D.  
Comparative copper coil-induced thrombogenicity of the internal mammary, left anterior descending coronary and popliteal arteries in dog.  
*Arterioscl. Thromb.* 12, 639-644, 1992.
305. Declerck P.J., Van Keer L., Verstreken M., Collen D.  
An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.  
*Thromb. Haemost.* 67, 95-100, 1992.
306. Lijnen H.R., Van Hoef B., Matsuo O., Collen D.  
On the molecular interactions between plasminogen-staphylokinase,  $\alpha_2$ -antiplasmin and fibrin.  
*Biochim. Biophys. Acta* 1118, 144-148, 1992.
307. Lijnen H.R., Webb P.D., Van Hoef B., De Cock F., Stassen J.M., Prior S.D., Collen D.  
Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.  
*Thromb. Haemost.* 67, 239-247, 1992.
308. Li X.K., Lijnen H.R., Nelles L., Van Hoef B., Stassen J.M., Collen D.  
Biochemical and biologic properties of rt-PA del(K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.  
*Blood* 79, 417-429, 1992.

309. Lijnen H.R., Stassen J.M., Rapold H.J., Nakamura H., Kobayashi Y., Collen D.  
Biochemical and biological properties of a recombinant chimera consisting of amino acid Asn-1 to Lys-12 of  $\alpha_2$ -antiplasmin (fibrin cross-linking site) and amino acids Leu-4 to Leu-411 of single chain urokinase-type plasminogen activator.  
*Fibrinolysis* 6, 87-98, 1992.
310. Nelles L., Li X.K., Vanlinthout I., De Cock F., Lijnen H.R., Collen D.  
Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G,K49N, a substitution variant of human tissue-type plasminogen activator.  
*Thromb. Haemost.* 67, 445-452, 1992.
311. Collen D., Nelles L., De Cock F., Lemmens G., Van Coetsem T., Demarsin E., Lijnen H.R.  
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.  
*Thromb. Res.* 65, 421-438, 1992.
312. Lijnen H.R., Li X.K., Nelles L., Hu M.H., Collen D.  
Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.  
*Eur. J. Biochem.* 205, 701-709, 1992.
313. Lu H.R., Gold H.K., Wu Z., Yasuda T., Pauwels P., Rapold H.J., Napier M., Bunting S., Collen D.  
G4120, an Arg-Gly-Asp containing pentapeptide enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.  
*Thromb. Haemost.* 67, 686-691, 1992.
314. Lu H.R., Wu Z., Pauwels P., Lijnen H.R., Collen D.  
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.  
*J. Am. Coll. Cardiol.* 19, 1350-1359, 1992.
315. Declerck P.J., De Mol M., Vaughan D.E., Collen D.  
Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator.  
*J. Biol. Chem.* 267, 11693-11696, 1992.
316. Imura Y., Stassen J.M., Collen D.  
Comparative antithrombotic effects of heparin, recombinant hirudin and Argatroban in a hamster femoral vein platelet-rich thrombosis model.  
*J. Pharm. Exper. Therap.* 261, 895-898, 1992.

317. Descheemaeker K.A., Wijns S., Nelles L., Auwerx J., Ny T., Collen D.  
Interaction of AP-1-like, AP-2-like and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response.  
*J. Biol. Chem.* 267, 15086-15091, 1992.
318. Collen D., Silence K., Demarsin E., De Mol M., Lijnen H.R.  
Isolation and characterization of natural and recombinant staphylokinase.  
*Fibrinolysis* 6, 203-213, 1992.
319. Lijnen H.R., Van Hoef B., Vandebossche L., Collen D.  
Biochemical properties of natural and recombinant staphylokinase.  
*Fibrinolysis* 6, 214-225, 1992.
320. Collen D., Zhao Z.A., Holvoet P., Marynen P.  
Primary structure and gene structure of staphylokinase.  
*Fibrinolysis* 6, 226-231, 1992.
321. Collen D., De Cock F., Vanlinthout I., Declerck P.J., Lijnen H.R., Stassen J.M.  
Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase.  
*Fibrinolysis* 6, 232-242, 1992.
322. Jang I.K., Gold H.K., Leinbach R.C., Rivera A.G., Fallon J.T., Bunting S., Collen D.  
Persistent inhibition of arterial thrombosis by a one hour intravenous infusion of Argatroban, a selective thrombin inhibitor.  
*Coron. Art. Dis.* 3, 407-414, 1992.
323. Imura Y., Stassen J.M., Kurokawa T., Iwasa S., Lijnen H.R., Collen D.  
Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.  
*Blood* 79, 2322-2329, 1992.
324. Lijnen H.R., Li X.K., Demarsin E., De Cock F., Nelles L., Collen D.  
Characterization of rt-PA I276G, a recombinant human tissue-type plasminogen activator mutant with altered plasmin cleavage site.  
*Fibrinolysis* 6, 149-159, 1992.
325. Vaughan D.E., Declerck P.J., Van Houtte E., De Mol M., Collen D.  
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.  
*Thromb. Haemost.* 68, 60-63, 1992.
326. Jang I.-K., Gold H.K., Leinbach R.C., Fallon J.T., Collen D., Wilcox J.N.  
Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis.  
*Arterioscl. Thromb.* 12, 948-954, 1992.

327. Dewerchin M., Vandamme A.-M., Holvoet P., De Cock F., Lemmens G., Lijnen H.R., Stassen J.M., Collen D.  
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.  
*Thromb. Haemost.* 68, 170-179, 1992.
328. Imura Y., Stassen J.M., Bunting S., Stockmans F., Collen D.  
Antithrombotic properties of L-cysteine,N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model.  
*Blood* 80, 1247-1253, 1992.
329. Arnout J., Simoons M., de Bono D., Rapold H.J., Collen D., Verstraete M.  
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).  
*J. Am. Coll. Cardiol* 20, 513-519, 1992.
330. Imura Y., Stassen J.M., Vreys I., Lesaffre E., Gold H.K., Collen D.  
Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and Argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.  
*Thromb. Haemost.* 68, 336-340, 1992.
331. Li X.K., Lijnen H.R., Nelles L., Hu M.H., Collen D.  
Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.  
*Biochim. Biophys. Acta* 1159, 37-43, 1992.
332. Bulens F., Thompson A.E., Stassen J.M., Moreau H., Declerck P.J., Nelles L., Collen D.  
Induction of t-PA synthesis with intravenous bolus injection of vitamin A palmitate in vitamin A deficient rats.  
*Fibrinolysis* 6, 243-249, 1992.
333. Descheemaeker K., Nelles L., Moreau H., Strandberg L., Ny T., Collen D.  
Transfection of human endothelial cells with plasminogen activator inhibitor type-1 promoter/reporter gene fragments reveals phorbol ester induction of gene expression.  
*Fibrinolysis* 6, 256-262, 1992.
334. Holvoet P., Laroche Y., Lijnen H.R., Van Hoef B., Brouwers E., De Cock F., Lauwereys M., Gansemans Y., Collen D.  
Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.  
*Eur. J. Biochem.* 210, 945-952, 1992.

335. Collen D., De Cock F., Stassen J.-M.  
Comparative immunogenicity and thrombolytic properties towards arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.  
*Circulation* 87, 996-1006, 1993.
336. Holvoet P., Dewerchin M., Stassen J.M., Lijnen H.R., Tollenaere T., Gaffney P.J., Collen D.  
Thrombolytic profiles of clot-targeted plasminogen activators: parameters determining potency and initial and maximal rates.  
*Circulation* 87, 1007-1016, 1993.
337. Holvoet P., Laroche Y., Stassen J.M., Lijnen H.R., Van Hoef B., Cock F., Van Houtven A., Gansemans Y., Matthyssens G., Collen D.  
Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.  
*Blood* 81, 696-703, 1993.
338. Lijnen H.R., Van Hoef B., Collen D.  
Interaction of staphylokinase with different molecular forms of plasminogen.  
*Eur. J. Biochem.* 211, 91-97, 1993.
339. Gold H.K., Torres F.W., Garabedian H.D., Werner W., Jang I.K., Kahn A., Hagstrom J.N., Yasuda T., Leinbach R.C., Newell J.B. Bovill E.G., Stump D.C., Collen D.  
Evidence for a rebound coagulation phenomenon after cessation of a 4 hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.  
*J. Am. Coll. Cardiol.* 21, 1039-1047, 1993.
340. Collen D., Schlott B., Engelborghs Y., Van Hoef B., Hartmann M., Lijnen H.R., Behnke D.  
On the mechanism of the activation of human plasminogen by recombinant staphylokinase.  
*J. Biol. Chem.* 268, 8284-8289, 1993.
341. Stassen J.M., Rapold H.J., Vanlinthout I., Collen D.  
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.  
*Thromb. Haemost.* 69, 454-459, 1993.
342. Silence K., Collen D., Lijnen H.R.  
Interaction between staphylokinase, plasmin(ogen) and  $\alpha_2$ -antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by  $\alpha_2$ -antiplasmin.  
*J. Biol. Chem.* 268, 9811-9816, 1993.

343. Yasuda T., Gold H.K., Kohmura C., Guerrero L., Yaoita H., Fallon J.T., Bunting S., Collen D.  
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.  
*Arterioscl. Thromb.* 13, 738-747, 1993.
344. Collen D., Van de Werf F.  
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.  
*Circulation* 87, 1850-1853, 1993.
345. Collen D., De Mol M., Demarsin E., De Cock F., Stassen J.M.  
Isolation and conditioning of recombinant staphylokinase for use in man.  
*Fibrinolysis* 7, 242-247, 1993.
346. Rapold H.J., Gold H.K., Wu Z., Napier M., Bunting S., Collen D.  
Effects of G4120, a Arg-Gly-Asp containing synthetic platelet glycoprotein IIb/IIIa receptor antagonist, on arterial and venous thrombolysis with recombinant tissue-type plasminogen activator in dogs.  
*Fibrinolysis* 7, 248-256, 1993.
347. Lijnen H.R., Van Hoef B., Smith R.A.G., Collen D.  
Functional properties of p-anisoylated plasmin-staphylokinase complex.  
*Thromb. Haemost.* 70, 326-331, 1993.
348. Lijnen H.R., Beelen V., Declerck P.J., Collen D.  
Bio-immunoassay for staphylokinase in blood.  
*Thromb. Haemost.* 70, 491-494, 1993.
349. Ueshima S., Silence K., Collen D., Lijnen H.R.  
Molecular conversions of recombinant staphylokinase during plasminogen activation in purified systems and in human plasma.  
*Thromb. Haemost.* 70, 495-499, 1993.
350. Silence K., Collen D., Lijnen H.R.  
Regulation by  $\alpha_2$ -antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma.  
*Blood* 82, 1175-1183, 1993.
351. Collen D., Van Hoef B., Schlott B., Hartmann M., Gührs K.H., Lijnen H.R.  
Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.  
*Eur. J. Biochem.* 216, 307-314, 1993.

352. Van de Werf F., Janssens L., Brzostek T., Mortelmans L., Wackers F.J.Th., Willems G.M., Heidbuchel H., Lesaffre E., Scheys I., Collen D., De Geest H.  
Short-term effects of early intravenous treatment with a  $\beta$ -adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.  
*J. Am. Coll. Cardiol.* 22, 407-416, 1993.
353. Vaughan D.E., Declerck P.J., Reilly T.M., Park K., Collen D., Fasman G.D.  
Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1).  
*Biochim. Biophys. Acta.* 1202, 221-229, 1993.
354. Van de Werf F., Lijnen H.R., Collen D.  
Coronary thrombolysis with K<sub>1</sub>K<sub>2</sub>P<sub>u</sub>, a chimeric tissue-type and urokinase-type plasminogen activator. A feasibility study in six patients with acute myocardial infarction.  
*Coron. Art. Dis.* 4, 929-933, 1993.
355. Carmeliet P., Kieckens L., Schoonjans L., Ream B., Van Nuffelen A., Prendergast G., Cole M., Bronson, R., Collen D., Mulligan R.C.  
Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.  
*J. Clin. Invest.* 92, 2746-2755, 1993.
356. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., van den Oord J.J., De Mol M., Mulligan R.C., Collen D.  
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis.  
*J. Clin. Invest.* 92, 2756-2760, 1993.
357. Declerck P.J., Boden G., Degreef H., Collen D.  
Influence of oral intake of retinoids on the human plasma fibrinolytic system.  
*Fibrinolysis* 7, 347-351, 1993.
358. Collen D., Lu H.R., Stassen J.M., Vreys I., Yasuda T., Bunting S., Gold H.K.  
Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.  
*Thromb. Haemost.* 71, 95-102, 1994.
359. Declerck P.J., Vanderschueren S., Billiet J., Moreau H., Collen D.  
Prevalence and induction of circulating antibodies against recombinant staphylokinase.  
*Thromb. Haemost.* 71, 129-133, 1994.
360. Ueshima S., Holvoet P., Lijnen H.R., Nelles L., Seghers V. Collen D.  
Expression and characterization of clustered charge-to-alanine mutants of low  $M_r$  single-chain urokinase-type plasminogen activator.  
*Thromb. Haemost.* 71, 134-140, 1994.



361. Holvoet P., Perez G., Bernar H., Brouwers E., Vanloo B., Rosseneu M., Collen D. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. *J. Clin. Invest.* 93, 89-98, 1994.
362. Schlott B., Hartmann M., Gührs K.H., Birch-Hirschfeld E., Pohl H.D., Vanderschueren S., Van de Werf F., Michoel A., Collen D., Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. *BioTechnology* 12, 185-189, 1994.
363. Kiss R., Lu H.R., Roskams T., Jang I.-K., Plow E.F., Gold H.K., Collen D. Time course of the effects of a single bolus injection of F(ab')<sub>2</sub> fragments of the antiplatelet GPIIb/IIIa antibody 7E3 on arterial eversion graft occlusion, platelet aggregation and bleeding time in dogs. *Arterioscl. Thromb.* 14, 367-374, 1994.
364. Kiss R.G., Stassen J.M., Deckmyn H., Roskams T., Gold H.K., Plow E.F., Collen D. Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. *Arterioscl. Thromb.* 14, 375-380, 1994.
365. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., van den Oord J.J., Collen D., Mulligan R.C. Physiological consequences of loss of plasminogen activator gene function in mice. *Nature* 368, 419-424, 1994.
366. Garabedian H.D., Gold H.K., Newell J.B., Collen D., Hagstrom J.N., Bovill E.G. Accelerated thrombin generation during anticoagulation in patients with unstable angina pectoris. *Blood* 83, 1155, 1994.
367. Schlott B., Hartmann M., Gührs K.H., Birch-Hirschfeld E., Gase A, Vettermann S., Collen D., Lijnen H.R. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. *Biochim. Biophys. Acta* 1204, 235-242, 1994.
368. Gase A., Birch-Hirschfeld E., Gührs K.-H., Hartmann M., Vetterman S., Damaschun G., Damaschun H., Gast K., Misselwitz R., Zirwer D., Collen D., Schlott B. The thermostability of natural variants of bacterial plasminogen-activator staphylokinase. *Eur. J. Biochem.* 223, 303-308, 1994.

369. Audenaert A.M., Knockaert I., Collen D., Declerck P.J.  
Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.  
*J. Biol. Chem.* 269, 19559-19564, 1994.
370. Collen D., Stassen J.M., Yasuda T., Refino C., Paoni N., Keyt B., Roskams T., Guerrero J.L., Lijnen H.R., Gold H.K., Bennett W.F.  
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-I-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.  
*Thromb. Haemost.* 72, 98-104, 1994.
371. Vanderschueren S.M.F., Stassen J.M., Collen D.  
On the immunogenicity of recombinant staphylokinase in patients and in animal models.  
*Thromb. Haemost.* 72, 297-301, 1994.
372. Lijnen H.R., De Cock F., Collen D.  
Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.  
*Eur. J. Biochem.* 224, 567-574, 1994.
373. Lijnen H.R., Van Hoef B., Beelen V., Collen D.  
Characterization of the murine plasma fibrinolytic system.  
*Eur. J. Biochem.* 224, 863-871, 1994.
374. Lijnen H.R., De Cock F., Van Hoef B., Schlott B., Collen D.  
Characterization of the interaction between plasminogen and staphylokinase.  
*Eur. J. Biochem.* 224, 143-149, 1994.
375. Stassen J.M., Nyström Å., Hoylaerts M., Collen D.  
Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.  
*Circulation* 91, 1330-1335, 1995.
376. Jun L., Arnout J., Vanhove Ph., Dol F., Lormeau J.-C., Herbert J.-M., Collen D., Van de Werf F.  
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.  
*Coron. Art. Dis.* 6, 257-263, 1995.
377. Bulens F., Ibanez-Tallon I., Van Acker P., De Vriese A., Nelles L., Belayew A., Collen D.  
Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases.  
*J. Biol. Chem.* 270, 7167-7175, 1995.

378. Declerck P., Carmeliet P., Verstreken M., De Cock F., Collen D.  
Generation of monoclonal antibodies against autologous proteins in gene-inactivated mice.  
*J. Biol. Chem.* 270, 8397-8400, 1995.
379. Rodriguez P., Fuentes P., Barro M., Alvarez J.G., Muñoz E., Collen D., Lijnen H.R.  
Structural domains of streptokinase involved in the interaction with plasminogen.  
*Eur. J. Biochem.* 229, 83-90, 1995.
380. Sloan M.A., Price T.R., Petito C.K., Randall A.M.Y., Solomon R.E., Terrin M.L., Gore J., Collen D., Kleiman N., Feit F., Babb J., Herman M., Roberts W.C., Sopko G., Bovill E., Forman S., Knatterud G.L.  
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The TIMI-II pilot and randomized clinical trial combined experience.  
*Neurology* 45, 649-658, 1995.
381. Lijnen H.R., Stassen J.M., Collen D.  
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.  
*Thromb. Haemost.* 73, 845-849, 1995.
382. Lijnen H.R., Van Hoef B., Collen D.  
Interactions of staphylokinase with human platelets.  
*Thromb. Haemost.* 73, 472-477, 1995.
383. Holvoet P., Perez G., Zhao Z., Brouwers E., Bernar H., Collen D.  
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.  
*J. Clin. Invest.* 95, 2611-2619, 1995.
384. Shatos M., Orfeo T., Doherty J.M., Penar P.L., Collen D., Mann K.G.  
Alpha thrombin stimulates urokinase production and DNA synthesis in cultured human cerebral microvascular endothelial cells.  
*Arterioscl. Thromb. Vasc. Biol.* 15, 903-911, 1995.
385. Vanderschueren S., Barrios L., Kerdsinchai P., Van den Heuvel P., Hermans L., Vrolix M., De Man F., Benit E., Muyltermans L., Collen D., Van de Werf F.  
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.  
*Circulation* 92, 2044-2049, 1995.
386. Vanderschueren S., Stockx L., Wilms G., Lacroix H., Verhaeghe R., Vermynen J., Collen D.  
Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase.  
*Circulation* 92, 2050-2057, 1995.

387. Ploplis V.A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E.F., Collen D.  
Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice.  
*Circulation* 92, 2585-2593, 1995.
388. Declerck P.J., Verstreken M., Collen D.  
Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.  
*Thromb. Haemost.* 74, 1305-1309, 1995.
389. Holvoet P., Zhao Z., Vanloo B., Vos R., Deridder E., Dhoest A., Taveirne J., Brouwers E., Demarsin E., Engelborghs Y., Rosseneu M., Collen D., Brasseur R.  
Phospholipid binding and lecithin-cholesterol acyltransferase activation properties of apolipoprotein A-I mutants.  
*Biochemistry* 34, 13334-13342, 1995.
390. Rodriguez P., Collen D., Lijnen H.R.  
Binding of streptokinase and staphylokinase to plasminogen.  
*Fibrinolysis* 9, 298-303, 1995.
391. Lijnen H.R., Moons L., Beelen V., Carmeliet P., Collen D.  
Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.  
*Thromb. Haemost.* 74, 1126-1131, 1995.
392. Silence K., Hartmann M., Gührs K.-H., Gase A., Schlott B., Collen D., Lijnen H.R.  
Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis.  
*J. Biol. Chem.* 270, 27192-27198, 1995.
393. Lijnen H.R., Wnendt S., Schneider J., Janocha E., Van Hoef B., Collen D., Steffens G.J.  
Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.  
*Eur. J. Biochem.* 234, 350-357, 1995.
394. Leonardsson G., Peng X.-R., Liu K., Nordström L., Carmeliet P., Mulligan R., Collen D., Ny T.  
Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators.  
*Proc. Natl. Acad. Sci. USA* 92, 12446-12450, 1995.
395. Dewerchin M., Van Nuffelen A., Wallays G., Bouché A., Moons L., Carmeliet P., Mulligan R.C., Collen D.  
Generation and characterization of urokinase receptor-deficient mice.  
*J. Clin. Invest.* 97, 870-878, 1996.

396. Idusogie E., Rosen E., Geng J.P., Carmeliet P., Collen D., Castellino F.J.  
Characterization of a cDNA encoding murine coagulation factor VII.  
*Thromb. Haemost.* 75, 481-487, 1996.
397. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoek A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A.  
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.  
*Nature* 380, 435-439, 1996.
398. Vanderschueren S., Collen D.  
Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.  
*Thromb. Haemost.* 75, 816-819, 1996.
399. Lijnen H.R., Silence K., Hartmann M., Gührs K.-H., Gase A., Schlott B., Collen D.  
Fibrinolytic properties of staphylokinase mutants obtained by "clustered charge-to-alanine" mutagenesis.  
*Fibrinolysis* 10, 177-182, 1996.
400. Vanderschueren S., Stassen J.M., Collen D.  
Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model.  
*J. Cardiovasc. Pharmacol.* 27, 809-815, 1996.
401. Bugge T.H., Flick M.J., Danton M.J.S., Daugherty C.C., Romer J., Danø K., Carmeliet P., Collen D., Degen J.L.  
Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.  
*Proc. Natl. Acad. Sci. USA* 93, 5899-5904, 1996.
402. Collen D., Bernaerts R., Declercq P., De Cock F., Demarsin E., Jenné S., Laroche Y., Lijnen H.R., Silence K., Verstreken M.  
Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization.  
*Circulation* 94, 197-206, 1996.
403. Collen D., Moreau H., Stockx L., Vanderschueren S.  
Recombinant staphylokinase variants with altered immunoreactivity. II. Thrombolytic properties and antibody induction.  
*Circulation* 94, 207-216, 1996.
404. Ding H., Descheemaeker K., Marynen P., Nelles L., Carvalho T., Carmo-Fonseca M., Collen D., Belayew A.  
Characterization of a helicase-like transcription factor involved in the expression of the human plasminogen activator inhibitor-1 gene.  
*DNA Cell Biol.* 15, 429-442, 1996.

405. Janssens S., Bloch K.D., Nong Z., Gerard R.D., Zoldhelyi P., Collen D.  
Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats.  
*J. Clin. Invest.* 98, 317-324, 1996.
406. Holvoet P., Zhao Z., Deridder E., Dhoest A., Collen D.  
Effects of deletion of the carboxyl-terminal domain of apo A-I or of its substitution with helices of apo A-II on in vitro and in vivo lipoprotein association.  
*J. Biol. Chem.* 271, 19395-19401, 1996.
407. Lijnen H.R., Carmeliet P., Bouché A., Moons L., Ploplis V.A., Plow E.F., Collen D.  
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.  
*Blood* 88, 870-876, 1996.
408. Carmeliet P., Mackman N., Moons L., Luther T., Gressens P., Van Vlaenderen I., Demunck H., Kasper M., Breier G., Evrard Ph., Muller M., Risau W., Edgington T., Collen D.  
Role of tissue factor in embryonic blood vessel development.  
*Nature* 383, 73-75, 1996.
409. Huang Y.-Y., Bach M.E., Lipp H.-P., Zhuo M., Wolfer D.P., Hawkins R.D., Schoonjans L., Kandel E.R., Godfraind J.-M., Mulligan R., Collen D., Carmeliet P.  
Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways.  
*Proc. Natl. Acad. Sci. USA* 93, 8699-8704, 1996.
410. Vanderschueren S., Collen D., Van de Werf F.  
A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis.  
*Thromb. Haemost.* 76, 541-544, 1996.
411. Nong Z., Stassen J.M., Moons L., Collen D., Janssens S.  
Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling.  
*Circulation* 94, 1941-1947, 1996.
412. Gase A., Hartmann M., Gührs K.-H., Röcker A., Collen D., Behnke D., Schlott B.  
Functional significance of NH<sub>2</sub>- and COOH-terminal regions of staphylokinase in plasminogen activation.  
*Thromb. Haemost.* 76, 755-760, 1996.
413. Holvoet P., Donck J., Landeloos M., Brouwers E., Luytens K., Arnout J., Lesaffre E., Vanrenterghem Y., Collen D.  
Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.  
*Thromb. Haemost.* 76, 663-669, 1996.

414. Schoonjans L., Albright G.M., Li J.-L., Collen D., Moreadith R.W.  
Pluripotential rabbit embryonic stem (ES) cells are capable of forming overt coat color chimeras following injection into blastocysts.  
*Mol. Reprod. Develop.* 45, 439-443, 1996.
415. Lijnen H.R., Van Hoef B., Collen D.  
Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.  
*Eur. J. Biochem.* 241, 840-848, 1996.
416. Okada K. Lijnen H.R., Moreau H., Vanderschueren S., Collen D.  
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.  
*Thromb. Haemost.* 76, 857-859, 1996.
417. Idusogie E., Rosen E.D., Carmeliet P., Collen D., Castellino F.J.  
Nucleotide structure and characterization of the murine blood coagulation Factor VII gene.  
*Thromb. Haemost.* 76, 957-964, 1996.
418. Bulens F., Merchiers P., Ibanez-Tallon I., De Vriese A., Nelles L., Claessens F., Belayew A., Collen D.  
Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene.  
*J. Biol. Chem.* 272, 663-671, 1997.
419. Carmeliet P., Moons L., Ploplis V., Plow E., Collen D.  
Impaired arterial neointima formation in mice with disruption of the plasminogen gene.  
*J. Clin. Invest.* 99, 200-208, 1997.
420. Collen D., De Cock F., Demarsin E., Jenné S., Lasters I., Laroche Y., Warmerdam P., Jespers L.  
Recombinant staphylokinase variants with altered immunoreactivity. III. Species variability of antibody binding patterns.  
*Circulation* 95, 455-462, 1997.
421. Collen D., Stockx L., Lacroix H., Suy R., Vanderschueren S.  
Recombinant staphylokinase variants with altered immunoreactivity. IV. Identification of variants with reduced antibody induction but intact potency.  
*Circulation* 95, 463-472, 1997.
422. Lijnen, H.R., Wagner E.F., Collen D.  
Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.  
*Thromb. Haemost.* 77, 362-367, 1997.

- 422a. De Geest B., Zhao Z., Collen D., Holvoet P.  
Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice.  
*Circulation* 96, 4349-4356, 1997.
- 422b. Jespers L., Jenné S., Lasters I., Collen D.  
Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage.  
*J. Mol. Biol.* 269, 704-718, 1997.
423. Carmeliet P., Moons L., Stassen J.M., De Mol M., Bouché A., van den Oord J.J., Kockx M., Collen D.  
Vascular wound healing and neointima formation induced by perivascular electric injury in mice.  
*Am. J. Pathol.* 150, 761-776, 1997.
424. Schlott B., Gührs K.H., Hartmann M., Röcker A., Collen D.  
Staphylokinase requires NH<sub>2</sub>-terminal proteolysis for plasminogen activation.  
*J. Biol. Chem.* 272, 6067-6072, 1997.
425. Conway E.M., Pollefeyt S., Collen D., Steiner-Mosonyi M.  
The amino terminal lectin-like domain of thrombomodulin is required for constitutive endocytosis.  
*Blood* 89, 652-661, 1997.
426. Bulens F., Moreau H., De Vriese A., Nelles L., Collen D.  
Hormonal regulation of the expression of fibrinolytic components in HT1080 fibrosarcoma and endothelial cells.  
*Fibrinol. Proteol.* 11, 57-63, 1997.
427. Kitching A.R., Holdsworth S.R., Ploplis V.A., Plow E.F., Collen D., Carmeliet P., Tipping P.G.  
Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis.  
*J. Exp. Med.* 185, 963-968, 1997.
428. Lasters I., Van Herzeele N., Lijnen H.R., Collen D., Jespers L.  
Enzymatic properties of phage-displayed fragments of human plasminogen.  
*Eur. J. Biochem.* 244, 946-952, 1997.
429. Holvoet P., Danloy S., Collen D.  
Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism. A study based on deletion and substitution variants in transgenic mice.  
*Eur. J. Biochem.* 245, 642-647, 1997.
430. Lijnen H.R., Lasters I., Verstreken M., Collen D., Jespers L.  
Screening panels of monoclonal antibodies using phage-displayed antigen.  
*Anal. Biochem.* 248, 211-215, 1997.



431. Dhoest A., Zhao Z., De Geest B., Deridder E., Sillen A., Engelborghs Y., Collen D., Holvoet P.  
Role of the Arg<sup>123</sup>-Tyr<sup>166</sup> paired helix of apo A-I in lecithin:cholesterol acyltransferase activation.  
*J. Biol. Chem.* 272, 15967-15972, 1997.
432. Rolling F., Nong Z., Pisvin S., Collen D.  
Adeno-associated virus mediated gene transfer into rat carotid arteries.  
*Gene Ther.* 4, 757-761, 1997.
433. Benotmane A.M., Hoylaerts M.F., Collen D., Belayew A.  
Nonisotopic quantitative analysis of protein-DNA interactions at equilibrium.  
*Anal. Biochem.* 250, 181-185, 1997.
434. Baes M., Gressens P., Baumgart E., Carmeliet P., Casteels M., Fransen M., Evrard Ph., Fahimi D., Declercq P.E., Collen D., Van Veldhoven P.P., Mannaerts G.P.  
A mouse model for Zellweger syndrome.  
*Nature Gen.* 17, 49-57, 1997.
435. Carmeliet P., Stassen J.M., Van Vlaenderen I., Meidell R.S., Collen D., Gerard R.D.  
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.  
*Blood* 90, 1527-1534, 1997.
436. Okada K., Lijnen H.R., Dewerchin M., Belayew A., Matsuo O., Collen D., Bernaerts R.  
Characterization and targeting of the murine  $\alpha_2$ -antiplasmin gene.  
*Thromb. Haemost.* 78, 1104-1110, 1997.
437. Vanderschueren S., Van Vlaenderen I., Collen D.  
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.  
*Stroke* 28, 1783-1788, 1997.
438. Carmeliet P., Moons L., Lijnen R., Janssens S., Lupu F., Collen D., Gerard R.D.  
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice.  
*Circulation* 96, 3180-3191, 1997.
439. Vanderschueren S., Dens J., Kerdsinchai P., Desmet W., Vrolix M., De Man F., Van den Heuvel P., Hermans L., Collen D., Van de Werf F.  
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.  
*Am. Heart J.* 134, 213-219, 1997.

440. Nong Z., Hoylaerts M., Van Pelt N., Collen D., Janssens S.  
Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats.  
*Circ. Res.* 81, 865-869, 1997.
441. Carmeliet P., Moons L., Herbert J.M., Crawley J., Lupu F., Lijnen R., Collen D.  
Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice.  
*Circ. Res.* 81, 829-839, 1997.
442. Rosen E.D., Chan J.C.Y., Idusogie E., Clotman F., Vlasuk G., Luther T., Jalbert L.R., Albrecht S., Zhong L., Lissens A., Schoonjans L., Moons L., Collen D., Castellino F.J., Carmeliet P.  
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding.  
*Nature* 390, 290-294, 1997.
443. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaître V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., Collen D.  
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.  
*Nature Gen.* 17, 439-444, 1997.
444. Carmeliet P., Moons L., Dewerchin M., Rosenberg S., Herbert J.M., Lupu F., Collen D.  
Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.  
*J. Cell Biol.* 140, 233-245, 1998.
445. Chuah M.K.L., Brems H., Vanslembrouck V., Collen D., VandenDriessche T.  
Bone marrow stromal cells as targets for gene therapy of hemophilia A.  
*Hum. Gene Ther.* 9, 353-365, 1998.
446. Tracy R.P., Kleiman N.S., Thompson B., Cannon C.P., Bovill E.G., Brown R.G., Collen D., Mahan E., Mann K.G., Rogers W.J., Sopko G., Stump D.C., Williams D.O., Zaret B.L., for the TIMI II investigators.  
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.  
*Am. Heart J.* 135, 29-37, 1998.
447. Heymans S., Verhaeghe R., Stockx L., Collen D.  
Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis.  
*Thromb. Haemost.* 79, 517-519, 1998.

448. Holvoet P., Theilmeier G., Shivalkar B., Flameng W., Collen D.  
LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth and compensatory vessel enlargement in coronary arteries of miniature pigs.  
*Arterioscl. Thromb. Vasc. Biol.* 18, 415-422, 1998.
449. Holvoet P., Stassen J.M., Van Cleemput J., Collen D., Vanhaecke J.  
Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease.  
*Arterioscl. Thromb. Vasc. Biol.* 18, 100-107, 1998.
450. Lijnen H.R., Silence J., Van Hoef B., Collen D.  
Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice.  
*Blood* 91, 2045-2053, 1998.
451. Jalbert L., Rosen E.D., Lissens A., Carmeliet P., Collen D., Castellino F.J.  
Nucleotide structure and characterization of the murine gene encoding anticoagulant Protein C.  
*Thromb. Haemost.* 79, 310-316, 1998.
452. Ploplis V.A., French E.L., Carmeliet P., Collen D., Plow E.F.  
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice.  
*Blood* 91, 2005-2009, 1998.
453. Lijnen H.R., Van Hoef B., Soloway P., Collen D.  
Plasminogen/plasmin system function in mice deficient in stromelysin-1 (MMP-3) or in tissue inhibitor of metalloproteinases type 1 (TIMP-1).  
*Fibrinol. Proteol.* 12, 1-8, 1998.
454. Janssens S., Flaherty D., Nong Z., Varenne O., Van Pelt N., Hausermans C., Zoldhelyi P., Gerard R., Collen D.  
Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats.  
*Circulation* 97, 1274-1281, 1998.
455. Lijnen H.R., Ugwu F., Bini A, Collen D.  
Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3).  
*Biochemistry* 37, 4699-4702, 1998.
456. Jespers L., Van Herzeele N., Lijnen H.R., Van Hoef B., De Maeyer M., Collen D., Lasters I.  
Arginine 719 in human plasminogen mediates formation of the staphylokinase:plasmin activator complex.  
*Biochemistry* 37, 6380-6386, 1998.

457. Ugwu F., Van Hoef B, Bini A, Collen D., Lijnen H.R.  
Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).  
*Biochemistry* 37, 7231-7236, 1998.
458. Lijnen H.R., Silence J., Lemmens G., Frederix L., Collen D.  
Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.  
*Thromb. Haemost.* 79, 1171-1176, 1998.
459. Lijnen H.R., Van Hoef B., Lupu F., Moons L., Carmeliet P., Collen D.  
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.  
*Arterioscler. Thromb. Vasc. Biol.* 18, 1035-1045, 1998.
460. Liang Z., Cooper A. DeFord M.E., Carmeliet P., Collen D., Castellino F.J., Rosen E.D.  
Cloning and characterization of a cDNA encoding murine coagulation factor X.  
*Thromb. Haemost.* 80, 87-91, 1998.
461. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C.J., Ratcliffe P., Moons L., Jain R.K., Collen D., Keshert E.  
Role of HIF-1 $\alpha$  in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis.  
*Nature* 394, 485-490, 1998.
462. Bajou K., Noël A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., Foidart J.M.  
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.  
*Nature Med.* 4, 923-928, 1998.
463. Holvoet P., Danloy S., Deridder E., Lox M., Bernar H., Dhoest A., Collen D.  
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.  
*J. Clin. Invest.* 102, 379-385, 1998.
464. Lijnen H.R., Ugwu F., Rio M.C., Collen D.  
Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11).  
*Fibrinol. Proteol.* 12, 155-164, 1998.
465. Sinnaeve P., Roelants I., Van de Werf F., Collen D.  
Feasibility study of a liquid formulation of recombinant staphylokinase for coronary artery thrombolysis.  
*Fibrinol. Proteol.* 12, 173-177, 1998.

466. Schlott B., Gührs K.H., Hartmann M., Röcker A., Collen D.  
NH<sub>2</sub>-terminal structural motifs in staphylokinase required for plasminogen activation.  
*J. Biol. Chem.* 273, 22346-22350, 1998.
467. Varenne O., Pislaru S., Gillijns H., Van Pelt N., Gerard R.D., Zoldhelyi P., Van de Werf F., Collen D., Janssens S.P.  
Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs.  
*Circulation* 98, 919-926, 1998.
468. Jenné S., Brepoels K., Collen D., Jespers L.  
High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library.  
*J. Immunol.* 161, 3161-3168, 1998.
469. Plow E.F., Ploplis V.A., Busuttill S., Carmeliet P., Collen D.  
A role of plasminogen in atherosclerosis and restenosis models in mice.  
*Thromb. Haemost.* 82 (Suppl 1), 4-7, 1999.
470. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., Collen D.  
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.  
*Circulation* 98, 1487-1494, 1998.
471. Ding H., Beckers M.C., Plaisance S., Marynen P., Collen D., Belayew A.  
Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous to 3.3 kb dispersed repeated elements.  
*Hum. Mol. Genet.* 7, 1681-1694, 1998.
472. Jalbert L.R., Rosen E.D., Moons L., Chan J.C.Y., Carmeliet P., Collen D., Castellino F.J.  
Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.  
*J. Clin. Invest.* 102, 1481-1488, 1998.
473. Moons L., Shi C., Ploplis V., Plow E., Haber E., Collen D., Carmeliet P.  
Reduced transplant arteriosclerosis in plasminogen-deficient mice.  
*J. Clin. Invest.* 102, 1788-1797, 1998.
474. Praus M., Wauterickx K., Collen D., Gerard R.D.  
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors.  
*Gene Ther.* 6, 227-236, 1999.
475. Rabijns A., De Bondt H.L., Collen D., De Ranter C.  
A fully functional deletion staphylokinase derivative crystallizes in two non-isomorphous monoclinic modifications.  
*Acta Crystallogr. D55*, 709-711, 1999

476. Chan J.C.Y., Carmeliet P., Moons L., Rosen E.D., Huang Z.F., Broze G.J. Jr., Collen D., Castellino F.J.  
Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit.  
*J. Clin. Invest.* 103, 475-482, 1999.
477. Lijnen H.R., Okada K., Matsuo O., Collen D., Dewerchin M.  
 $\alpha_2$ -Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding.  
*Blood* 93, 2274-2281, 1999.
478. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., Perriard J.C., Dewerchin M., Flameng W., Nagy A., Lupu F., Moons L., Collen D., D'Amore P.A., Shima D.T.  
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF<sub>164</sub> and VEGF<sub>188</sub>.  
*Nature Med.* 5, 495-502, 1999.
479. Jespers L., Vanwetswinkel S., Lijnen H.R., Van Herzeele N., Van Hoef B., Demarsin E., Collen D., De Maeyer M.  
Structural and functional basis of plasminogen activation by staphylokinase.  
*Thromb. Haemost.* 81, 479-485, 1999.
480. Varenne O., Gerard R.D., Sinnaeve P., Gillijns H., Collen D., Janssens S.  
Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?  
*Human Gene Ther.* 10, 1105-1115, 1999.
481. Nagai N., De Mol M., Lijnen H.R., Carmeliet P., Collen D.  
Role of plasminogen system components in focal cerebral ischemic infarction. A gene targeting and gene transfer study in mice.  
*Circulation* 99, 2440-2444, 1999.
482. Lijnen H.R., Lupu F., Moons L., Carmeliet P., Goulding D., Collen D.  
Temporal and topographic matrix metalloproteinase expression after vascular injury in mice.  
*Thromb. Haemost.* 81, 799-807, 1999.
483. Rabhi-Sabile S., Steiner-Mosonyi M., Pollefeyt S., Collen D., Pouvelle B., Gysin J., Boffa M.C., Conway E.M.  
Plasmodium Falciparum–Infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin.  
*Thromb. Haemost.* 81, 815-821, 1999.
484. Conway E.M., Pollefeyt S., Cornelissen J., DeBaere I., Steiner-Mosonyi M., Weitz J.I., Weiler-Guettler H., Carmeliet P., Collen D.  
Structure-function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development.  
*Blood* 93, 3442-3450, 1999.

485. Matsuno H., Kozawa O., Niwa M., Ueshima S., Matsuo O., Collen D., Uematsu T. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. *Thromb. Haemost.* 81, 601-604, 1999.
486. Kataoka K., Asai T., Taneda M., Ueshima S., Matsuo O., Kuroda R., Carmeliet P., Collen D. Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. *Neuroscience Lett.* 266, 220-222, 1999.
487. Lijnen H.R., Soloway P., Collen D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. *Circulation Res.* 85, 1186-1191, 1999.
488. Holvoet P., Collen D., Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. *JAMA* 281, 1718-1721, 1999.
489. Merchiers P., De Vriese A., Bulens F., Collen D., Belayew A. Thyroid hormone inhibits transcription of the human tissue-type plasminogen activator gene promoter. *Fibrinolysis & Proteolysis* 13, 104-112, 1999.
490. Plow E.F., Ploplis V.A., Carmeliet P., Collen D. Plasminogen and cell migration in vivo. *Fibrinolysis & Proteolysis* 13, 49-53, 1999.
491. Carmeliet P., Lampugnani M.-G., Moons L., Breviaro F., Compornolle V., Bono F., Balconi G., Spagnuolo R., Oosthuysen B., Dewerchin M., Zanetti A., Angelillo A., Mattot V., Nuyens D., Lutgens E., Clotman F., de Ruiter M.C., Gittenberger-de Groot A., Poelmann R., Lupu F., Herbert J.-M., Collen D., Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. *Cell* 98, 147-157, 1999.
492. Ding H., Benotmane A.M., Suske G., Collen D., Belayew A. Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human PAI-1 gene. *J. Biol. Chem.* 274, 19573-19580, 1999.
493. Gabriels J., Beckers M.C., Ding H., De Vriese A., Plaisance S., van der Maarel S., Padberg G.W., Frants R.R., Hewitt J.E., Collen D., Belayew A. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 236, 25-32, 1999.

494. Merchiers P., Bulens F., De Vriese A., Collen D., Belayew A.  
Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue-type plasminogen activator gene.  
FEBS Lett. 456, 149-154, 1999.
495. Jespers L., Lijnen H.R., Vanwetswinkel S., Van Hoef B., Brepoels K., Collen D., De Maeyer M.  
Guiding a docking mode by phage display: Selection of correlated mutations at the staphylokinase-plasmin interface.  
J. Mol. Biol. 290, 471-479, 1999.
496. Ugwu F., Lemmens G., Collen D., Lijnen H.R.  
Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).  
Thromb. Haemost. 82, 1127-1131, 1999.
497. Varenne O., Gerard R.D., Sinnaeve P., Gillijns H., Collen D., Janssens S.  
Percutaneous adenoviral gene transfer into porcine coronary arteries: Is catheter-based gene delivery adapted to coronary circulation?  
Human Gene Therapy 10, 1105-1115, 1999.
498. VandenDriessche T., Vanslembrouck V., Goovaerts I., Zwinnen H., Vanderhaeghen M.L., Collen D., Chuah M.K.L.  
Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.  
Proc. Natl. Acad. Sci. USA 96, 10379-10384, 1999.
499. Heymans S., Lutun A., Nuyens D., Theilmeier G., Creemers E., Moons L., Dyspersin G.D., Cleutjens J.P.M., Shipley M., Angellilo A., Levi M., Nüsse O., Baker A., Keshet E., Lupu F., Herbert J.M., Smits J.F.M., Shapiro S.D., Baes M., Borgers M., Collen D., Daemen M.J.A.P., Carmeliet P.  
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.  
Nature Med. 5, 1135-1142, 1999.
500. Theilmeier G., Lenaerts T., Remacle C., Collen D., Vermylen J., Hoylaerts M.F.  
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress.  
Blood 94, 2725-2734, 1999.
501. Merchiers P., Bulens F., Stockmans I., De Vriese A., Convents R., Bouillon R., Collen D., Belayew A., Carmeliet G.  
1,25-dihydroxyvitamin D<sub>3</sub> induction of the tissue-type plasminogen activator gene is mediated through its multihormone-responsive enhancer.  
FEBS Lett. 460, 289-296, 1999.
502. Sinnaeve P., Varenne O., Collen D., Janssens S.  
Gene therapy in the cardiovascular system: an update.  
Cardiovasc. Res. 44, 498-506, 1999.



503. Nagai N., Vanlinthout I., Collen D.  
Comparative effects of tissue-type plasminogen activator, streptokinase and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.  
*Circulation* 100, 2541-2546, 1999.
504. Lijnen H.R., Van Hoef B., Vanlinthout I., Verstreken M., Rio M.C., Collen D.  
Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation.  
*Arterioscler. Thromb. Vasc. Biol.* 19, 2863-2870, 1999.
505. De Geest B., Stengel D., Landeloos M., Lox M., Le Gat L., Collen D., Holvoet P., Ninio E.  
Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase – Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis.  
*Arterioscl. Thromb. Vasc. Biol.* 20, E68-E75, 2000.
506. Lijnen H.R., Van Hoef B., Ugwu F., Collen D., Roelants I.  
Specific proteolysis of human plasminogen by 24 kDa endopeptidase from a Novel *Chryseobacterium Sp.*  
*Biochemistry* 39, 479-488, 2000.
507. De Geest B., Van Linthout S., Lox M., Collen D., Holvoet P.  
Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: Role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer.  
*Hum. Gene Ther.* 11, 101-112, 2000.
508. Holvoet P., De Geest B., Van Linthout S., Lox M., Danloy S., Raes K., Collen D.  
The Arg<sup>123</sup>-Tyr<sup>166</sup> central domain of human ApoAI is critical for lecithin:cholesterol acyltransferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenic mice.  
*Arterioscler. Thromb. Vasc. Biol.* 20, 459-466, 2000.
509. Conway E.M., Pollefeyt S., Cornelissen J., De Baere I., Steiner-Mosonyi M., Ong K., Baens M., Collen D., Schuh A.C.  
Three differentially expressed *survivin* cDNA variants encode proteins with distinct antiapoptotic functions.  
*Blood* 95, 1435-1442, 2000.
510. Dewerchin M., Liang Z., Moons L., Carmeliet P., Castellino F.J., Collen D., Rosen E.D.  
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.  
*Thromb. Haemost.* 83, 185-190, 2000.

511. Vanwetswinkel S., Plaisance S., Zhang Z.Y., Vanlinthout I., Brepoels K., Lasters I., Collen D., Jespers L.  
Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase.  
*Blood* 95, 936-942, 2000.
512. Holvoet P., Van Cleemput J., Collen D., Vanhaecke J.  
Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease.  
*Arterioscler. Thromb. Vasc. Biol.* 20, 698-702, 2000.
513. Chuah M.K.L., Van Damme A., Zwinnen H., Goovaerts I., Vanslembrouck V., Collen D., VandenDriessche T.  
Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.  
*Hum. Gene Ther.* 11, 729-738, 2000.
514. Chan J.C.Y., Cornelissen I., Collen D., Ploplis V.A., Castellino F.J.  
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.  
*J. Clin. Invest.* 105, 897-903, 2000.
515. Lijnen H.R., Lupu F., Collen D., Le Naour F., Boucheix C.  
CD9 gene deficiency does not affect smooth muscle cell migration and neointima formation after vascular injury in mice.  
*Thromb. Haemost.* 83, 956-961, 2000.
516. Morange P.E., Lijnen H.R., Alessi M.C., Kopp F., Collen D., Juhan-Vague I.  
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.  
*Arterioscler. Thromb. Vasc. Biol.* 20, 1150-1154, 2000.
517. Heymans S., Vanderschueren S., Verhaeghe R., Stockx L., Lacroix H., Nevelsteen A., Laroche Y., Collen D.  
Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion.  
*Thromb. Haemost.* 83, 666-671, 2000.
518. Armstrong P.W., Burton J.R., Palisaitis D., Thompson C.R., Van de Werf F., Rose B., Collen D., Teo K.K.  
Collaborative Angiographic Patency Trial of Recombinant Staphylokinase (CAPTORS).  
*Am. Heart J.* 139, 820-823, 2000.
519. Nishida T., Matsuno H., Kozawa O., Ueshima S., Matsuo O., Collen D., Uematsu T.  
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.  
*J. Cardiovasc. Pharm.* 36, 770-775, 2000.

520. Lijnen H.R., Van Hoef B., Dewerchin M., Collen D.  
 $\alpha_2$ -Antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury.  
Arterioscler. Thromb. Vasc. Biol. 20, 1488-1492, 2000.
521. Herreman A., Serneels L., Annaert W., Collen D., Schoonjans L., De Strooper B.  
Total inactivation of  $\gamma$ -secretase activity in presenilin-deficient embryonic stem cells.  
Nature Cell Biol. 2, 461-462, 2000.
522. Varenne O., Sinnaeve P., Gillijns H., Iung B., Laurysens V., Meurrens K., Bout B., Valerio D., Collen D., Janssens S.P., Gerard R.D.  
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries.  
Human Gene Ther. 11, 1329-1339, 2000.
523. Jacquemin P., Durviaux S.M., Jensen J., Godfraind C., Gradwohl G., Guillemot F., Madsen O.D., Carmeliet P., Dewerchin M., Collen D., Rousseau G.G., Lemaigre F.P.  
Transcription factor hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls expression of the proendocrine gene *ngn3*.  
Mol. Cell. Biol. 20, 4445-4454, 2000.
524. Baes M., Huyghe S., Carmeliet P., Declercq P.E., Collen D., Mannaerts G.P., Van Veldhoven P.P.  
Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids.  
J. Biol. Chem. 275, 16329-16336, 2000.
525. Laroche Y., Heymans S., Capaert S., De Cock F., Demarsin E., Collen D.  
Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes.  
Blood 96, 1425-1432, 2000.
526. Lijnen H.R., Van Hoef B., Roelants I., Collen D.  
Fibrin(ogen) degradation by a 24k-endopeptidase from *Chryseobacterium Sp.*  
Fibrinol. Proteol. 14, 247-252, 2000.
527. Collen D., Sinnaeve P., Demarsin E., Moreau H., De Maeyer M., Jespers L., Laroche Y., Van de Werf F.  
Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction.  
Circulation 102, 1766-1772, 2000.
528. Theilmeier G., De Geest B., Van Veldhoven P.P., Stengel D., Michiels C., Lox M., Landeloos M., Chapman M.J., Ninio E., Collen D., Himpens B., Holvoet P.  
HDL-associated PAF-AH reduces endothelial adhesiveness in apoE<sup>-/-</sup> mice.  
FASEB J. 14, 2032-2039, 2000.

529. Matsuno H., Kozawa O., Ueshima S., Matsuo O., Collen D., Uematsu T.  
Lack of t-PA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice.  
Thromb. Haemost. 83, 605-609, 2000.
530. Creemers E., Cleutjens J., Smits J., Moons L., Collen D., Daemen M., Carmeliet P.  
Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction.  
Am. J. Pathol. 156, 1865-1873, 2000.
531. Lijnen H.R., Ugwu F., Maquoi E., Lemmens G., Van Hoef B., Dewerchin M., Collen D.  
Vascular and cellular proteolytic activity in mice with  $\alpha_2$ -antiplasmin gene inactivation.  
Fibrinol. Proteol. 14, 322-326, 2000.
532. Arza B., Hoylaerts M.F., F  lez J., Collen D., Lijnen H.R.  
Prostromelysin-1 (proMMP-3) stimulates plasminogen activation by tissue-type plasminogen activator.  
Eur. J. Biochem. 267, 6378-6384, 2000.
533. Arza B., F  lez J., F  bregas P., Laroche Y., Collen D., Lijnen H.R.  
Plasminogen binding properties of macrophage inflammatory protein (MIP)-2 $\alpha$ .  
Thromb. Haemost. 84, 71-77, 2000.
534. Budts W., Pokreisz P., Nong Z.X., Van Pelt N., Gillijns H., Gerard R., Lyons R., Collen D., Bloch K.D., Janssens S.  
Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodelling in rats  
Circulation 102, 2880-2885, 2000.
535. Lijnen H.R., Arza B., Van Hoef B., Collen D., Declerck P.J.  
Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).  
J. Biol. Chem. 275, 37645-37650, 2000.
536. Matsuno H., Kozawa O., Ueshima S., Matsuo O., Collen D., Uematsu T.  
The interaction between components of the fibrinolytic system and GPIIb/IIIa of platelets thrombus formation in mice  
Br. J. Pharmacol. 131, 858-864, 2000.
537. Lijnen H.R., Van Hoef B., Collen D.  
Inactivation of the serpin  $\alpha_2$ -antiplasmin by stromelysin-1.  
Biochim. Biophys. Acta 1547, 206-213, 2001.
538. Moons L., Vanlinthout I., Roelants I., Moreadith R., Collen D., Rapold H.J.  
Toxicology studies with recombinant staphylokinase and with SY161-P5, a polyethylene glycol-derivatized cysteine-substitution mutant.  
Toxicol. Pathol. 29, 285-291, 2001.

539. Angelillo-Scherrer A., Garcia de Frutos P., Aparicio C., Melis E., Savi P., Lupu F., Arnout J., Dewerchin M., Hoylaerts M.F., Herbert J.M., Collen D., Dahlbäck B., Carmeliet P.  
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.  
*Nature Med.* 7, 215-221, 2001.
540. De Geest B., Van Linthout S., Collen D.  
Sustained expression of human apo A-I following adenoviral gene transfer in mice.  
*Gene Therapy* 8, 121-127, 2001.
541. Arza B., De Maeyer M., Felez J., Collen D., Lijnen H.R.  
Critical role of glutamic acid 202 in the enzymatic activity of stromelysin-1 (MMP-3).  
*Eur. J. Biochem.* 268, 826-831, 2001.
542. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J.M., Noel A.S.  
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies.  
*J. Cell Biol.* 152, 777-784, 2001.
543. Beckers M., Gabriels J., van der Maarel S., De Vriese A., Frants R.R., Collen D., Belayew A.  
Active genes in junk DNA? Characterization of DUX genes embedded within 3.3 kb repeated elements.  
*Gene* 264, 51-57, 2001.
544. Sinnaeve P., Chiche J.D., Nong Z., Varenne O., Van Pelt N., Gillijns H., Collen D., Bloch K.D., Janssens S.  
Soluble guanylate cyclase  $\alpha 1$  and  $\beta 1$  gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects.  
*Circ. Res.* 88, 103-109, 2001.
545. Carmeliet P., Moons L., Luttun A., Vincenti V., Compernelle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., Scholz D., Acker T., DiPalma T., Dewerchin M., Noel A., Stalmans I., Barra A., Blacher S., Vandendriessche Th., Ponten A., Eriksson U., Plate K.H., Foidart J.-M., Schaper W., Charnock-Jones S., Hicklin D.J., Herbert J.-M., Collen D., Persico M.G.  
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.  
*Nature Med.* 7, 575-583, 2001.
546. Lijnen H.R., Bloemmen F., Vereecken A., Collen D.  
Enzyme-linked immunosorbent assay for the specific detection of angiostatin-like plasminogen moieties in biological samples.  
*Thromb. Res.* 102, 53-59, 2001.

547. Ugwu F., Lemmens G., Collen D., Lijnen H.R.  
Matrix metalloproteinase deficiencies do not impair cell-associated fibrinolytic activity.  
*Thromb. Res.* 102, 61-69, 2001.
548. Nagai N., De Mol M., Van Hoef B., Verstreken M., Collen D.  
Depletion of circulating  $\alpha_2$ -antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.  
*Blood* 97, 3086-3092, 2001.
549. Levi M., Moons L., Bouché A., Shapiro S.D., Collen D., Carmeliet P.  
Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. *Circulation* 103, 2014-2020, 2001.
550. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G., Michiels C., Raes M., Bult H., Collen D., Van Veldhoven P., Ninio E., Holvoet P.  
Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.  
*Circulation* 103; 2495-2500, 2001.
551. Holvoet P., Mertens A., Verhamme P., Bogaerts K., Beyens G., Verhaeghe R., Collen D., Muls E., Van de Werf F.  
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.  
*Arterioscler Thromb Vasc Biol* 21; 844-848, 2001.
552. Oosthuysen B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudénbach V., Vermeylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., Carmeliet P.  
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.  
*Nat. Gen.* 28, 131-138, 2001.
553. Nuyens D., Stengl M., Dugarmaa S., Rossenbacher T., Compennolle V., Rudy Y., Smits J.F., Flameng W., Clancy C.E., Moons L., Vos M.A., Dewerchin M., Benndorf K., Collen D., Carmeliet E., Carmeliet P.  
Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome  
*Nature Med.* 7, 1021-1027, 2001.

554. Melis E., Moons L., De Mol M., Herbert J.M., Mackman N., Collen D., Carmeliet P., Dewerchin M.  
Targeted deletion of the cytosolic domain of tissue factor in mice does not affect development.  
*Biochem. Biophys. Res. Comm.* 286, 580-586, 2001.
555. Dewerchin M., Collen D., Lijnen H.R.  
Enhanced fibrinolytic potential in mice with combined homozygous deficiency of  $\alpha_2$ -antiplasmin and PAI-1.  
*Thromb. Haemost.* 86, 640-646, 2001.
556. Silence J., Lupu F., Collen D., Lijnen H.R.  
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation.  
*Arterioscler. Thromb. Vasc. Biol.* 21, 1440-1445, 2001.
557. Brusselmans K., Bono F., Maxwell P., Dor Y., Dewerchin M., Collen D., Herbert J.M., Carmeliet P.  
Hypoxia-inducible factor-2 $\alpha$  (HIF-2 $\alpha$ ) is involved in the apoptotic response to hypoglycaemia, but not to hypoxia.  
*J. Biol. Chem.* 276, 39192-39196, 2001.
558. Van Cromphaut S.J., Dewerchin M., Hoenderop J.G.J., Stockmans I., Van Herck E., Kato S., Bindels R.J.M., Collen D., Carmeliet P., Bouillon R., Carmeliet G.  
Duodenal calcium absorption in vitamin D receptor-knock out mice: functional and molecular aspects.  
*Proc. Natl. Acad. Sci. USA* 98, 13324-13329, 2001.
559. Ver Heyen M.V., Heymans S., Antoons G., Reed T., Periasamy M., Awede B., Lebacqz J., Vangheluwe P., Dewerchin M., Collen D., Sipido K., Carmeliet P., Wuytack F.  
Replacement of the muscle-specific sarcoplasmic reticulum Ca<sup>2+</sup>-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.  
*Circ. Res.* 89, 838-846, 2001.
560. Vermeersch P., Nong Z., Stabile E., Varenne O., Gillijns H., Van Pelt N., Hoylaerts M., De Scheerder I., Collen D., Janssens S.  
L-Arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanism.  
*Arterioscler. Thromb. Vasc. Biol.* 21, 1604-1609, 2001.
561. Warmerdam P.A.M., Vanderlick K., Vandervoort P., De Smedt H., Plaisance S., De Maeyer M., Collen D.  
Staphylokinase-specific cell-mediated immunity in humans.  
*J. Immunol.* 168, 155-161, 2002.

562. Morange P.E., Bastelica D., Bonzi M.F., Van Hoef B., Collen D., Juhan-Vague I., Lijnen H.R.  
Influence of t-PA and u-PA on adipose tissue development in a murine model of diet-induced obesity.  
*Thromb. Haemost.* 87, 306-310, 2002.
563. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouché A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., D'Amore P.A.  
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.  
*J. Clin. Invest.* 109, 327-336, 2002.
564. Maes C., Carmeliet P., Moermans K., Stockmans I., Smets N., Collen D., Bouillon R., Carmeliet G.  
Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF<sub>164</sub> and VEGF<sub>188</sub>.  
*Mech. Develop.* 111, 61-73, 2002.
565. Baes M., Dewerchin M., Janssen A., Collen D., Carmeliet P.  
Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes.  
*Genesis* 32, 177-178, 2002.
566. Lijnen H.R., Maquoi E., Hansen L.B., Van Hoef B., Frederix L., Collen D.  
Matrix metalloproteinase inhibition impairs adipose tissue development in mice.  
*Arterioscler. Thromb. Vasc. Biol.* 22, 374-379, 2002.
567. Lijnen H.R., Van Hoef B., Frederix L., Rio M.C., Collen D.  
Adipocyte hypertrophy in stromelysin-3 deficient mice with nutritionally induced obesity.  
*Thromb. Haemost.* 87, 530-535, 2002.
568. Lutun A., Lupu F., Storkebaum E., Hoylaerts M.F., Moons L., Crawley J., Bono F., Poole A.R., Tipping P., Herbert J.M., Collen D., Carmeliet P.  
Lack of plasminogen activator inhibitor-1 (PAI-1) promotes growth and abnormal matrix remodelling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.  
*Arterioscler. Thromb. Vasc. Biol.* 22, 499-505, 2002.
569. Maquoi E., Munaut C., Colige A., Collen D., Lijnen H.R.  
Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity.  
*Diabetes* 51, 1093-1101, 2002.
570. Singh I., Smith A., Vanzielegem B., Collen D., Burnand K., Saint-Remy J.M., Jacquemin M.  
Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.  
*Blood* 99, 3235-3240, 2002.



571. Silence J., Collen D., Lijnen H.R.  
Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene.  
*Circ. Res.* 90, 897-903, 2002
572. Van Damme A., VandenDriessche T., Collen D., Chuah M.K.L.  
Bone marrow stromal cells and mesenchymal stem cells as targets for gene therapy.  
*Curr. Gene Ther.* 2, 195-209, 2002.
573. Warmerdam P.A.M., Plaisance S., Vanderlick K., Vandervoort P., Brepoels K., Collen D., De Maeyer M.  
Elimination of a human T-cell region epitopes in staphylokinase by T-cell screening and computer modeling.  
*Thromb. Haemost.* 87, 666-673, 2002.
574. Mattot V., Moons L., Lupu F., Chernavvsky D., Gómez R.A., Collen D., Carmeliet P.  
Loss of the VEGF<sub>164</sub> and VEGF<sub>188</sub> isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice.  
*J. Am. Soc. Nephrol.* 13, 1548-1560, 2002.
575. Theilmeyer G., Michiels C., Spaepen E., Vreys I., Collen D., Vermynen J., Hoylaerts M.F.  
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.  
*Blood* 99, 4486-4493, 2002.
576. Van Linthout S., Collen D., De Geest B.  
Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.  
*Hum. Gene Ther.* 13, 829-840, 2002.
577. Sinnaeve P., Chiche J.D., Gillijns H., Van Pelt N., Wirthlin D., Van de Werf F., Collen D., Bloch K.D., Janssens S.  
Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis.  
*Circulation* 105, 2911-2916, 2002.
578. Compernelle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., Nemery B., Dewerchin M., Van Veldhoven P., Plate K., Moons L., Collen D., Carmeliet P.  
Loss of HIF-2 $\alpha$  and inhibition of VEGF-signalling impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.  
*Nat. Med.* 8, 702-710, 2002.

579. VandenDriessche T., Thorrez L., Naldini L., Follenzi A., Moons L., Berneman Z., Collen D., Chuah M.K.L.  
Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo.  
*Blood* 100, 813-822, 2002.
580. Theilmeyer G., Verhamme P., Dymarkowski S., Beck H., Bernar H., Lox M., Janssens S., Herregods M.C., Verbeken E., Collen D., Plate K., Flameng W., Holvoet P.  
Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density.  
*Circulation* 106, 1140-1146, 2002.
581. Lijnen H.R., Maquoi E., Demeulemeester D., Van Hoef B., Collen D.  
Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity.  
*Thromb. Haemost.* 88, 345-353, 2002.
582. Luttun A., Brusselmans K., Fukao H., Tjwa M., Ueshima S., Herbert J.M., Matsuo O., Collen D., Carmeliet P., Moons L.  
Loss of placental growth factor protects mice against vascular permeability in pathological conditions.  
*Biochem. Biophys. Res. Commun.* 295, 428-434, 2002.
583. Conway E.M., Pollefeyt S., Steiner-Mosonyi M., Luo W., Devriese A., Lupu F., Bono F., Leducq N., Dol F., Schaeffer P., Collen D., Herbert J.M.  
Deficiency of survivin in transgenic mice exacerbates Fas-induced apoptosis via mitochondrial pathways.  
*Gastroenterol.* 123, 619-631, 2002.
584. Theilmeyer G., Quarck R., Verhamme P., Bochaton-Piallat M.L., Lox M., Bernar H., Janssens S., Kockx M., Gabbiani G., Collen D., Holvoet P.  
Hypercholesterolemia impairs vascular remodelling after porcine coronary angioplasty.  
*Cardiovasc Res.* 55, 385-395, 2002.
585. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Priller J., De Klerck B., Compennolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., Carmeliet P.  
Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.  
*Nat. Med.* 8, 831-840, 2002.

586. Conway E.M., Van De Wouwer M., Pollefeyt S., Weitz J.I., Weiler H., Hellings P., Schaeffer P., Herbert J.M., Collen D., Theilmeier G.  
The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor  $\kappa$ B and mitogen-activated protein kinase pathways.  
*J. Exp. Med.* 196, 565-577, 2002.
587. Praus M., Collen D., Gerard R.D.  
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.  
*Int. J. Cancer* 102, 584-591, 2002.
588. Van Linthout S., Lusky M., Collen D., De Geest B.  
Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.  
*Gene Ther.* 9, 1520-1528, 2002.
589. Szelid Z., Sinnaeve P., Vermeersch P., Gillijns H., Pellens M., Laurysens V., Van Pelt N., Flameng W., Sergeant P., Herijgers P., Pokreisz P., Van Zonneveld A., Verbeken E., Collen D., Janssens S.  
Pre-existing anti-adenoviral immunity and regional myocardial gene transfer: modulation by nitric oxide.  
*Hum. Gene Ther.* 13, 2185-2195, 2002.
590. Chuah M.K.L., Schiedner G., Thorrez L., Brown B., Johnston M., Hertel S., Lillicrap D., Collen D., VandenDriessche T., Kochanek S.  
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.  
*Blood* 101, 1734-1743, 2003.
591. Schoonjans L., Kreemers V., Danloy S., Moreadith R.W., Laroche Y., Collen D.  
Improved generation of germline-competent embryonic stem cell lines from inbred mouse strains.  
*Stem Cells* 21, 90-97, 2003.
592. Lijnen H.R., Maquoi E., Morange P., Voros G., Van Hoef B., Kopp F., Collen D., Juhan-Vague I., Alessi M.C.  
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.  
*Arterioscler. Thromb. Vasc. Biol.* 23, 78-84, 2003.
593. Voros G., Maquoi E., Collen D., Lijnen H.R.  
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor- $\alpha$ , TNF- $\alpha$  converting enzyme and ADAMTS family members in murine fat territories.  
*Biochim. Biophys. Acta.* 1625, 36-42, 2003.

594. Lijnen H.R., Demeulemeester D., Van Hoef B., Collen D., Maquoi E.  
Deficiency of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) impairs nutritionally induced obesity in mice.  
Thromb. Haemost. 89, 249-255, 2003.
595. Van Damme A., Chuah M.K.L., Dell'Accio F., De Bari C., Luyten F., Collen D., VandenDriessche T.  
Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.  
Haemophilia 9, 94-103, 2003.
596. Maquoi E., Demeulemeester D., Voros G., Collen D., Lijnen H.R.  
Enhanced nutritionally induced adipose tissue development in mice with stromelysin-1 gene inactivation.  
Thromb. Haemost. 89, 696-704, 2003.
597. Janssens W., Chuah M.K.L., Naldini L., Follenzi A., Collen D., Saint-Remy J.M., VandenDriessche T.  
Efficiency of onco-retroviral and lentiviral gene transfer into primary mouse and human B-lymphocytes is pseudotype dependent.  
Hum. Gene Ther. 14, 263-276, 2003.
598. Singh I., Burnand K.G., Collins M., Luttun A., Collen D., Boelhouwer B., Smith A.  
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.  
Circulation 107, 869-875, 2003.
599. Stalmans I., Lambrechts D., Desmet F., Jansen S., Wang J., Maity S., Kneer P., von der Ohe M., Swillen A., Maes C., Gewillig M., Molin D.G.M., Hellings P., Boetel T., Haardt M., Compernelle V., Dewerchin M., Plaisance S., Vlietinck R., Emanuel B., Gittenberger-de Groot A.C., Scambler P., Morrow B., Driscoll D.A., Moons L., Esguerra C.V., Carmeliet G., Behn-Krappa A., Devriendt K., Collen D., Conway S.J., Carmeliet P.  
VEGF: a modifier of the *del22q11* (DiGeorge) syndrome?  
Nat. Med. 9, 173-182, 2003.
600. De Geest B.R., Van Linthout S.A., Collen D.  
Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells.  
Blood 101, 2551-2556, 2003.
601. Brusselmans K., Compernelle V., Tjwa M., Wiesener M.S., Maxwell P.H., Collen D., Carmeliet P.  
Heterozygous deficiency of hypoxia-inducible factor-2 $\alpha$  (HIF-2 $\alpha$ ) protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.  
J. Clin. Invest. 111, 1519-1527, 2003.

602. Nagai N., Demarsin E., Van Hoef B., Wouters S., Cingolani D., Laroche Y., Collen D. Recombinant human microplasmin: Production and potential therapeutic properties. *J. Thromb. Haemost.* 1, 307-313, 2003.
603. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Communi D., Shibuya M., Collen D., Conway E.M., Carmeliet P.  
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.  
*Nat. Med.* 9, 936-943, 2003.
604. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., Carmeliet P.  
VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.  
*Nat. Genet.* 34, 383-394, 2003.
605. Conway E.M., Zwerts F., Van Eygen V., De Vriese A., Nagai N., Luo W., Collen D.  
Survivin-dependent angiogenesis in ischemic brain: molecular mechanisms of hypoxia-induced up-regulation.  
*Am. J. Pathol.* 163, 935-946, 2003.
606. Janssen A., Gressens P., Grabenbauer M., Baumgart E., Schad A., Vanhorebeek I., Brouwers A., Declercq P.E., Fahimi D., Evrard P., Schoonjans L., Collen D., Carmeliet P., Mannaerts G., Van Veldhoven P., Baes M.  
Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues.  
*J Neurosci.* 23, 9732-9741, 2003.
607. Dewerchin M., Herault J.P., Wallays G., Petitou M., Schaeffer P., Millet L., Weitz JI, Moons L., Collen D., Carmeliet P., Herbert JM  
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin  
*Circ. Res.* 93, 1120-1126, 2003.
608. Compernelle V., Brusselmans K., Franco D., Moorman A., Dewerchin M., Collen D., Carmeliet P.  
Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1 alpha  
*Cardiovasc. Res.* 60, 569-579, 2003.

609. Lijnen HR., Van Hoef B., Umans K., Collen D.  
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)  
*J. Thromb Haemost.* 2, 16-22, 2004.
610. Dewerchin M., Van Der Elst L., Singh I., Grailly S., Saint-Remy JM., Collen D., Jacquemin M.  
Inhibition of factor VIII with a partially inhibitory human recombinant monoclonal antibody prevents thrombotic events in a transgenic model of type II HBS antithrombin deficiency in mice  
*J. Thromb. Haemost.* 2, 77-84, 2004.
611. Janssens S., Pokreisz P., Schoonjans L., Pellens M., Vermeersch P., Tjwa M., Jans P., Scherrer-Crosbie M., Picard M.H., Szelid Z., Gillijns H., Van de Werf F., Collen D., Bloch K.D.  
Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.  
*Circ. Res.* 94, 1256-1262, 2004.
612. Voros G., Maquoi E., Collen D., Lijnen H.R.  
Influence of membrane-bound tumor necrosis factor (TNF)-alpha on obesity and glucose metabolism.  
*J. Thromb. Haemost.* 2, 507-513, 2004.
613. Luttun A., Lutgens E., Manderveld A., Maris K., Collen D., Carmeliet P., Moons L.  
Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.  
*Circulation* 109, 1408-1414, 2004.
614. Van de Wouwer M., Collen D., Conway E.M.  
Thrombomodulin-protein C-EPCR system integrated to regulate coagulation and inflammation.  
*Arterioscler. Thromb. Vasc. Biol.* 24, 1374-1383, 2004.
615. Suzuki Y., Nagai N., Collen D.  
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.  
*J. Thromb. Haemost.* 2, 1617-1621, 2004.
616. Hocheppied T., Schoonjans L., Staelens J., Kreemers V., Danloy S., Puimege L., Collen D., Van Roy F., Libert C.  
Breaking the species barrier: derivation of germline-competent embryonic stem cells from *Mus spretus* x C57BL/6 hybrids.  
*Stem Cells* 22, 441-447, 2004.

617. Lievens J., Snoeys J., Vekemans K., Van Linthout S., De Zanger R., Collen D., Wisse E., De Geest B.  
The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer.  
*Gene Ther.* 11, 1523-1531, 2004.
618. Suzuki Y., Chen F., Ni Y., Marchal G., Collen D., Nagai N.  
Microplasmin reduces ischemic brain damage and improves neurological function in a rat stroke model monitored with MRI.  
*Stroke* 35, 2402-2406, 2004.
619. Heymans S., Lupu F., Terclavers S., Vanwetswinkel B., Herbert J.M., Baker A., Collen D., Carmeliet P., Moons L.  
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.  
*Am. J. Pathol.* 166, 15-25, 2005.
620. Li X., Tjwa M., Moons L., Fons P., Noel A., Ny A., Zhou J.M., Lennartsson J., Li H., Luttun A., Ponten A., Devy L., Bouche A., Oh H., Manderveld A., Blacher S., Communi D., Savi P., Bono F., Dewerchin M., Foidart J.M., Autiero M., Herbert J.M., Collen D., Heldin C.H., Eriksson U., Carmeliet P.  
Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors.  
*J. Clin. Invest.* 115, 118-127, 2005.
621. Angelillo-Scherrer A., Burnier L., Flores N., Savi P., Demol M., Schaeffer P., Herbert J.M., Lemke G., Goff S.P., Matsushima G.K., Earp H.S., Vesin C., Hoylaerts M.F., Plaisance S., Collen D., Conway E.M., Wehrle-Haller B., Carmeliet P.  
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy.  
*J. Clin. Invest.* 115, 237-246, 2005.
622. Brusselmans K., Bono F., Collen D., Herbert J.M., Carmeliet P., Dewerchin M.  
A novel role for VEGF as an autocrine survival factor for embryonic stem cells during hypoxia.  
*J. Biol. Chem.* 280, 3493-3499, 2005.
623. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., Carmeliet P.  
Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.  
*Nat. Neurosci.* 8, 85-92, 2005.

624. Demeulemeester D., Collen D., Lijnen H.R.  
Effect of matrix metalloproteinase inhibition on adipose tissue development.  
*Biochem. Biophys. Res. Commun.* 329, 105-110, 2005.
625. Rossenbacker T., Mubagwa K., Jongbloed R.J., Vereecke J., Devriendt K., Gewillig M., Carmeliet E., Collen D., Heidebüchel H., Carmeliet P.  
Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.  
*Circulation* 111, 961-968, 2005.
626. Maquoi E., Voros G., Collen D., Lijnen H.R.  
Role of Gas6 in adipogenesis and nutritionally induced adipose tissue development in mice.  
*Arterioscler. Thromb. Vasc. Biol.* 25, 1002-1007, 2005.
627. Rossenbacker T., Schollen E., Kuiperi C., de Ravel T.J., Devriendt K., Matthijs G., Collen D., Heidebüchel H., Carmeliet P.  
Unconventional intronic splice site mutation in SCN5A associates with cardiac sodium channelopathy.  
*J. Med. Genet.* 42, e29, 2005.
628. Lambrechts D., Devriendt K., Driscoll D.A., Goldmuntz E., Gewillig M., Vlietinck R., Collen D., Carmeliet P.  
Low expression VEGF haplotype increases the risk for tetralogy of Fallot: a family based association study.  
*J. Med. Genet.* 42, 519-522, 2005.
629. Khurana R., Moons L., Shafi S., Luttun A., Collen D., Martin J.F., Carmeliet P., Zachary I.C.  
Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation.  
*Circulation* 111, 2828-2836, 2005.
630. Nagai N., Suzuki Y., Van Hoef B., Lijnen H.R., Collen D.,  
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.  
*J. Thromb. Haemost.* 3, 1379-1384, 2005.
631. Ny A., Koch M., Schneider M., Neven E., Tong R.T., Maity S., Fischer C., Plaisance S., Lambrechts D., Héligon C., Terclavers S., Ciesiolka M., Kälin R., Man W.Y., Senn I., Wyns S., Lupu F., Brändli A., Vleminckx K., Collen D., Dewerchin M., Conway E.M., Moons L., Jain R.K., Carmeliet P.  
A genetic *Xenopus laevis* tadpole model to study lymphangiogenesis.  
*Nat. Med.* 11, 998-1004, 2005.



632. Snoeys J., Mertens G., Lievens J., van Berkel T., Collen D., Biessen E.A.L., De Geest B.  
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.  
*Mol. Ther.* 11, 998-1004, 2006.
633. Acker T., Diez-Juan A., Aragonés J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., Riedel J., Elvert G., Flamme I., Maxwell P.H., Collen D., Dewerchin M., Jain R.K., Plate K.H., Carmeliet P.  
Genetic evidence for a tumor suppressor role of HIF-2 $\alpha$ .  
*Cancer Cell* 8, 131-141, 2005.
634. Voros G., Maquoi E., Demeulemeester D., Clerx N., Collen D., Lijnen H.R.  
Modulation of angiogenesis during adipose tissue development in murine models of obesity.  
*Endocrinology* 146, 4545-4554, 2005.
635. Melis E., Moons L., Arnout J., Hoylaerts M.F., Collen D., Carmeliet P., Dewerchin M.  
Thrombophilia in mice expressing a tissue factor variant lacking its transmembrane and cytosolic domain.  
*Biochem. Biophys. Res. Commun.* 333, 488-495, 2005.
636. Lijnen H.R., Alessi M.C., Van Hoef B., Collen D., Juhan-Vague I.  
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.  
*J. Thromb. Haemost.* 3, 1174-1179, 2005.
637. Van Damme A., Thorrez L., Ma L., Vandenburgh H., Eyckmans J., Dell'Accio F., De Bari C., Luyten F., Lillcrap D., Collen D., VandenDriessche T., Chuah M.K.  
Efficient lentiviral transduction and improved engraftment of human bone marrow mesenchymal cells.  
*Stem Cell* 24, 896-907, 2006.
638. Semeraro F., Voros G., Collen D., Lijnen H.R.  
Impairment of adipose tissue development by hypoxia is not mediated by plasminogen activator inhibitor-I.  
*Thromb. Haemost.* 95, 174-181, 2006.
639. Jacquemin M., Radcliffe C.M., Lavend'Homme R., Wormald M.R., Vanderelst L., Wallays G., Dewaele J., Collen D., Vermynen J., Dwek R.A., Saint-Remy J.M., Rudd P.M., Dewerchin M.  
Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.  
*J. Thromb. Haemost.* 4, 1047-1055, 2006.

640. Pokreisz P., Fleming I., Kiss L., Barbosa-Sicard E., Fisslthaler B., Falck J.R., Hammock B.D., Kim I.H., Szelid Z., Vermeersch P., Gillijns H., Pellens M., Grimminger F., van Zonneveld A.J., Collen D., Busse R., Janssens S.  
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling.  
*Hypertension* 47, 762-770, 2006.
641. Demeulemeester D., Scroyen I., Voros G., Snoeys J., De Geest B., Collen D., Lijnen H.R.  
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.  
*Thromb. Haemost.* 95, 1019-1024, 2006.
642. De Meyer S.F., Vanhoorelbeke K., Chuah M.K., Pareyn I., Gillijns V., Hebbel R.P., Collen D., Deckmyn H., VandenDriessche T.  
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor.  
*Blood* 107, 4728-4736, 2006.
643. Snoeys J., Mertens G., Lievens J., van Berkel T., Collen D., Biessen E.A., De Geest B.  
Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer.  
*Mol. Ther.* 13, 98-107, 2006.
644. Thorrez L., Vandeburgh H., Callewaert N., Mertens N., Shansky J., Wang L., Arnout J., Collen D., Chuah M., VandenDriessche T.  
Angiogenesis enhances Factor IX delivery and persistence from retrievable human bioengineered muscle implants.  
*Mol. Ther.* 14, 442-451, 2006.
645. Van de Wouwer M., Plaisance S., De Vriese A., Waelkens E., Collen D., Persson J., Daha M.R., Conway E.M.  
The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.  
*J. Thromb. Haemost.* 4, 1813-1824, 2006.
646. Lijnen H.R., Christiaens V., Scroyen I., Voros G., Tjwa M., Carmeliet P., Collen D.  
Impaired adipose tissue development in mice with inactivation of placental growth factor function.  
*Diabetes* 55, 2698-2704, 2006.
647. Voros G., Sandy J.D., Collen D., Lijnen H.R.  
Expression of aggrecan(ases) during murine preadipocyte differentiation and adipose tissue development.  
*Biochim. Biophys. Acta.* 1760, 1837-1844, 2006.

648. VandenDriessche T., Thorrez L., Acosta-Sanchez A., Petrus I., Wang L., Ma L., De Waele L., Iwasaki Y., Gillijns V., Wilson J.M., Collen D., Chuah M.K.  
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 versus lentiviral vectors for hemophilia B gene therapy.  
*J. Thromb. Haemost.* 5, 16-24, 2006.
649. De Geest B., Snoeys J., Van Linthout S., Lievens J., Collen D.  
Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.  
*Hum. Gene Ther.* 16, 1439-1451, 2005.
650. Lijnen H.R., Alessi M.C., Frederix L., Collen D., Juhan-Vague I.  
Tiplaxtinin impairs nutritionally induced obesity in mice.  
*Thromb. Haemost.* 96, 731-737, 2006.
651. Snoeys J., Lievens J., Wisse E., Jacobs F., Duimel H., Collen D., Frederik P., De Geest B.  
Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae.  
*Gene Ther.* 14, 604-612, 2007.
652. Verhamme P., Goossens G., Maleux G., Collen D., Stas M.  
A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.  
*J. Thromb. Thrombolysis.* 24,1-5, 2007.
653. Zwerts F., Lupu F., De Vriese A., Pollefeyt S., Moons L., Altura R.A., Jiang Y., Maxwell P.H., Hill P., Oh H., Rieker C., Collen D., Conway S.J., Conway E.M.  
Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure.  
*Blood* 109, 4742-4752, 2007.
654. Suzuki Y., Nagai N., Umemura K., Collen D., Lijnen H.R.  
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.  
*J. Thromb. Haemost.* 5, 1732-1739, 2007.
655. Lijnen H.R., Van Hoef B., Kemp D., Collen D.  
Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity.  
*Biochim. Biophys. Acta.* 1770, 1369-1373, 2007.
656. Vermeersch P., Buys E., Pokreisz P., Marsboom G., Ichinose F., Sips P., Pellens M., Gillijns H., Swinnen M., Graveline A., Collen D., Dewerchin M., Brouckaert P., Bloch K.D., Janssens S.  
Soluble guanylate cyclase- $\alpha$ 1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.  
*Circulation* 116, 936-943, 2007.

657. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., Autiero M., Wyns S., Plaisance S., Moons L., van Rooijen N., Giacca M., Stassen J.M., Dewerchin M., Collen D., Carmeliet P.  
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.  
*Cell* 131,463-75, 2007.
658. Esguerra C.V., Nelles L., Vermeire L., Ibrahim A., Crawford A.D., Derua R., Janssens E., Waelkens E., Carmeliet P., Collen D., Huylebroeck D.  
Ttrap is an essential modulator of Smad3-dependent Nodal signaling during zebrafish gastrulation and left-right axis determination.  
*Development* 134, 4381-4397, 2007.
659. Nagai N., Okada K., Kawao N., Ishida C., Ueshima S., Collen D., Matsuo O.  
Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.  
*Neurosci Lett.* 431, 46-49, 2008.
660. Peeters K., Stassen J.M., Collen D., Van Geet C., Freson K.  
Emerging treatments for thrombocytopenia: Increasing platelet production.  
*Drug Discov Today* 13, 798-806, 2008.
661. Marsboom G., Pokreisz P., Gheysens O., Vermeersch P., Gillijns H., Pellens M., Liu X., Collen D., Janssens S.  
Sustained endothelial progenitor cell dysfunction after chronic hypoxia-induced pulmonary hypertension.  
*Stem Cells.* 26, 1017-1026, 2008.
662. Angelillo-Scherrer A., Burnier L., Lambrechts D., Fish R.J., Tjwa M., Plaisance S., Sugamele R., De Mol M., Martinez-Soria E., Maxwell P.H., Lemke G., Goff S.P., Matsushima G.K., Earp H.S., Chanson M., Collen D., Izui S., Shapira M., Conway E.M., Carmeliet P.  
Role of Gas6 in erythropoiesis and anemia in mice.  
*J Clin Invest.* 118, 583-596, 2008.
663. Szelid Z., Pokreisz P., Liu X.S., Vermeersch P., Marsboom G., Gillijns H., Pellens M., Verbeken E., Van de Werf F., Collen D., Janssens SP.  
Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury.  
*Basic research in Cardiology* 105, 169-179, 2010.
664. Roncal C., Buyschaert I., Gerdes N., Georgiadou M., Ovchinnikova O., Fischer C., Stassen J.M., Moons L., Collen D., De Bock K., Hansson G.K., Carmeliet P.  
Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions.  
*Cardiovascular Research* 86, 29-36, 2010.

665. Van de Veire S., Stalmans I., Heindryckx F., Oura H., Tijeras-Raballand A., Schmidt T., Loges S., Albrecht I., Jonckx B., Vinckier S., Van Steenkiste C., Tugues S., Rolny C., De Mol M., Dettori D., Hainaud P., Coenegrachts L., Contreres J.O., Van Bergen T., Cuervo H., Xiao W.H., Le Henaff C., Buyschaert I., Masouleh B.K., Geerts A., Schomber T., Bonnin P., Lambert V., Haustraete J., Zacchigna S., Rakic J.M., Jimenez W., Noel A., Giacca M., Colle I., Foidart J.M., Tobelem G., Morales-Ruiz M., Vilar J., Maxwell P Vinores S.A., Carmeliet G., Dewerchin M., Claesson-Welsh L., Dupuy E., Van Vlierberghe H., Christofori G., Mazzone M., Detmar M., Collen D., Carmeliet P.  
Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease.  
*Cell*, 141, 178-190, 2010.
666. Dubois C., Liu X., Claus P., Marsboom G., Pokreisz P., Vandenwijngaert S., Dépelteau H., Streb W., Chaothawee L., Maes F., Gheysens O., Debyser Z., Gillijns H., Pellens M., Vandendriessche T., Chuah M., Collen D., Verbeken E., Belmans A., Van de Werf F., Bogaert J., Janssens S.  
Differential effects of progenitor cell Populations on left ventricular remodelling and myocardial neovascularisation after myocardial infarction.  
*J Am Coll Cardiol*, 18;55; 2232-43, 2010.
667. Wallays G., Nuyens D., Silasi-Mansat R., Souffreau J., Callaerts-Vegh Z., Van Nuffelen A., Moons L., D'Hooge R., Lupu F., Carmeliet P., Collen D., Dewerchin M.  
Notch3 Arg170Cys knock-in mice display pathologic and clinical features of the neurovascular disorder cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.  
*Arterioscler Thromb Vasc Biol*, 31, 2881-8, 2011.

## II. Review articles

1. Verstraete M., Vermeylen J., Collen D.  
Intravascular coagulation in liver disease.  
Ann. Rev. Med. 25, 447-455, 1974.
2. Collen D., De Maeyer L.  
Molecular biology of human plasminogen. I. Physicochemical properties and microheterogeneity.  
Thromb. Diathes. haemorrh. 34, 396-402, 1975.
3. Collen D., Verstraete M.  
Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man.  
Thromb. Diathes. haemorrh. 34, 403-408, 1975.
4. Collen D., Wiman B.  
Fast-acting plasmin inhibitor in human plasma: editorial review.  
Blood 51, 563-569, 1978.
5. Collen D., Wiman B.  
The fast-acting plasmin inhibitor of human plasma : The Prix Servier Lecture 1978.  
In: "Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 4". Ed.: J.F. Davidson.  
Churchill Livingstone, Edinburg, 1979, p. 11-19.
6. Collen D.  
Inhibitors of fibrinolysis.  
In: "Blood Coagulation and Haemostasis: A Practical Guide, 2nd Ed." Ed.: J.M. Thomson.  
Churchill Livingstone, Edinburgh, 1980, p. 261-278.
7. Collen D.  
Natural inhibitors of fibrinolysis.  
J. Clin. Pathol. 33, suppl. 14, 24-30, 1980.
8. Collen D.  
On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.  
Thromb. Haemost. 43, 77-89, 1980.
9. Collen D.  
Natural inhibitors of haemostasis, with particular reference to fibrinolysis.  
In: "Haemostasis and Thrombosis". Eds.: A.L. Bloom and D.P. Thomas. Churchill Livingstone, Edinburgh, 1981, p. 225-235.
10. Lijnen H.R., Collen D.  
Interaction of plasminogen activators and inhibitors with plasminogen and fibrin.  
Sem. Thromb. Hemost. 8, 2-10, 1982.

11. Collen D.  
Regulation of fibrinolysis. Plasminogen activator as a thrombolytic agent.  
In: "Pathobiology of the Endothelial Cell". Eds.: H.L. Nossel and H.J. Vogel. Academic Press, New York, 1982, p. 183-189.
12. Collen D., Verstraete M.  
Systemic thrombolytic therapy of acute myocardial infarction?  
Circulation 68, 462-465, 1983.
13. Collen D., Lijnen H.R.  
New approaches to thrombolytic therapy.  
Arteriosclerosis 4, 579-585, 1984.
14. Collen D.  
Coronary thrombolysis with tissue-type plasminogen activator : Prospective review.  
Texas Heart Inst. J. 11, 344-347, 1984.
15. Collen D.  
Human tissue-type plasminogen activator: from the laboratory to the bedside. Editorial.  
Circulation 72, 18-20, 1985.
16. Collen D.  
Tissue-type plasminogen activator: therapeutic potential in thrombotic disease states.  
Drugs 31, 1-5, 1986.
17. Collen D., Lijnen H.R.  
The fibrinolytic system in man.  
Crit. Rev. Oncol. Hemat. 4, 249-301, 1986.
18. Verstraete M., Collen D.  
Thrombolytic therapy in the eighties.  
Blood 67, 1529-1541, 1986.
19. Lijnen H.R., Collen D.  
Protease inhibitors of human plasma. Alpha-2-Antiplasmin.  
J. Med. 16, 225-284, 1985.
20. Verstraete M., Collen D.  
Pharmacology of thrombolytic drugs.  
J. Am. Coll. Cardiol. 8, 33B-40B, 1986.
21. Collen D.  
Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA). Potential for fibrin-specific thrombolytic therapy.  
Progr. Hemost. Thromb. 8, 1-18, 1986.
22. Collen D.  
Molecular mechanisms and clinical applications of thrombolysis.  
Les Cahiers de la Fondation Louis Jeantet de Médecine, Vol. 1, 1986, p. 41-54.

23. Stump D.C., Lijnen H.R., Collen D.  
Biochemical and biological properties of single-chain urokinase-type plasminogen activator.  
Cold Spring Harbor Symp. Quant. Biol. 51, 563-569, 1986.
24. Lijnen H.R., Stump D.C., Collen D.  
Single-chain urokinase-type plasminogen activator : mechanism of action and thrombolytic properties.  
Sem. Thromb. Haemost. 13, 152-159, 1987.
25. Collen D.  
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.  
J. Cell. Biochem. 33, 77-86, 1987.
26. Lijnen H.R., Collen D.  
Natural inhibitors of fibrinolysis.  
In: "Thrombosis and Haemostasis. 2nd Ed". Eds.: A.L. Bloom and D.P. Thomas. Churchill Livingstone, Edinburgh, 1987, p. 255-266.
27. Collen D., Lijnen H.R.  
Fibrinolysis and the control of hemostasis.  
In: "Molecular basis of blood diseases". Eds.: G. Stamatoyannopoulos, A.W. Nienhuis, P. Leder and P.W. Majerus. W.B. Saunders Co., Philadelphia, 1987, p. 662-688.
28. Stump D.C., Collen D.  
Single chain urokinase-type plasminogen activator.  
In : "Acute Coronary Intervention". Ed. : E.J. Topol. Alan R. Liss Inc., New York, 1987, p. 49-58.
29. Collen D., Topol E.J.  
Tissue-type plasminogen activator.  
In : "Acute Coronary Intervention". Ed.: E.J. Topol. Alan R. Liss Inc., New York 1987, p. 35-47.
30. Collen D., Stump D.C., Gold H.K.  
Thrombolytic therapy.  
Ann. Rev. Med. 39, 405-423, 1988.
31. Collen D.  
Synergism of thrombolytic agents. Investigational procedures and clinical potential.  
Circulation 77, 731-735, 1988.
32. Collen D.  
Plasminogen activators and thrombolytic therapy.  
ISI Atlas of Science: Pharmacology 3, 116-120, 1988.



33. Collen D., Juhan-Vague I.  
Fibrinolysis and atherosclerosis.  
Sem. Thromb. Haemost. 14, 180-183, 1988.
34. Lijnen H.R., Collen D.  
Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis.  
Fibrinolysis 3, 67-77, 1989.
35. Collen D., Lijnen H.R., Todd P.A., Goa K.L.  
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.  
Drugs 38, 346-388, 1989.
36. Collen D., Verstraete M.  
Anticoagulants, platelet-controlling drugs, and thrombolytic agents.  
In: "The Heart, Seventh Edition". Eds.: J.W. Hurst and R.C. Schlant. McGraw-Hill Information Sciences Company, New York, 1990, p. 1781-1787.
37. Collen D., Lijnen H.R.  
Plasminogen activators.  
Coron. Art. Dis. 1, 8-12, 1990.
38. Collen D.  
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?  
Ann. Int. Med. 112, 529-538, 1990.
39. Collen D., Lijnen H.R.  
Molecular mechanisms of thrombolysis: implications for therapy.  
Biochem. Pharmacol. 40, 177-186, 1990.
40. Collen D., Lijnen H.R.  
Molecular and cellular basis of fibrinolysis.  
In: "Hematology: Basic Principles and Practice". Eds.: R. Hoffman, E.J. Benz Jr., S.J. Shattil, B. Furie and H.J. Cohen. Churchill Livingstone, NY 1991, p 1232-1242.
41. Lijnen H.R., Collen D.  
Towards the development of improved thrombolytic agents.  
Br. J. Haematol. 77, 261-266, 1991.
42. Collen D.  
On the future of thrombolytic therapy in acute myocardial infarction.  
In: "Thrombolysis: Basic Contributions and Clinical Progress". Eds.: E. Braunwald and E. Haber. Mosby Yearbook, St. Louis, 1991, p. 315-331.
43. Lijnen H.R., Collen D.  
Strategies for the improvement of thrombolytic agents.  
Thromb. Haemost. 66, 88-110. 1991.

44. Collen D.  
Thrombolysis: is there a future for thrombolytic therapy in acute myocardial infarction.  
*Curr. Opinion Cardiol.* 6, 552-558, 1991.
45. Collen D., Lijnen H.R., Gold H.K.  
Towards better thrombolytic therapy.  
*Progr. Cardiovasc. Dis.* 34, 101-112, 1991.
46. Dewerchin M., Collen D.  
Enhancement of the thrombolytic potency of plasminogen activators by conjugation with clot-specific monoclonal antibodies.  
*Bioconj. Chem.* 2, 293-300, 1991.
47. Collen D., Lijnen H.R.  
Basic and clinical aspects of fibrinolysis and thrombolysis.  
*Blood* 78, 3114-3124, 1991.
48. Collen D.  
Designing thrombolytic agents: focus on safety and efficacy.  
*Am. J. Cardiol.* 69, 71A-81A, 1992.
49. Collen D.  
Trials comparing the available thrombolytic agents.  
*Coron. Art. Dis.* 3, 117-122, 1992.
50. Sobel B.E., Collen D.  
Questions unresolved by the Third International Study of Infarct Survival.  
*Am. J. Cardiol.* 70, 385-389, 1992.
51. Juhan-Vague I., Collen D.  
On the role of coagulation and fibrinolysis in atherosclerosis.  
*Ann. Epidemiol.* 2, 427-438, 1992.
52. Collen D.  
Recent developments in thrombolytic therapy.  
*Tschr. Ned. Veren. Klin. Chemie* 18, 125-127, 1993
53. Lijnen H.R., Collen D.  
Development of chimeric tissue-type/urokinase-type plasminogen activators for thrombolytic therapy.  
*Curr. Opin. Invest. Drugs* 2, 495-504, 1993.
54. Collen D., Lijnen H.R., Stassen J.M.  
Combination of animal models and biotechnologies in the development of new thrombolytic agents.  
*Fibrinolysis* 7, Suppl. 1, 36-38, 1993.

55. Stassen J.M., Collen D.  
In vivo models for experimental thrombolysis.  
*Fibrinolysis* 7, Suppl. 1, 39, 1993.
56. Lijnen H.R., Collen D.  
Experimental studies in thrombolysis and fibrinolysis.  
*Curr. Opin. Cardiol.* 8, 613-620, 1993.
57. Lijnen H.R., Collen D.  
Molecular mechanisms of inhibition of fibrinolysis.  
*Sangre* 37, Suppl 3, 76-83, 1992.
58. Collen D.  
Towards improved thrombolytic therapy.  
*Lancet* 342, 34-36, 1993.
59. Collen D.  
Unresolved issues after the available comparative trials of thrombolytic agents in acute myocardial infarction.  
*Zeitschr. Kardiol.* 82, Suppl 2, 119-123, 1993.
60. Collen D., Verstraete M.  
Thrombolytic agents.  
In: "Coronary thrombolysis in perspective", Eds: B.E. Sobel and D. Collen. Marcel Dekker Inc, New York, N.Y. 1993, p 11-34.
61. Sobel B.E., Collen D.  
Controversy and clarification: preliminary results of the GUSTO trial.  
In: "Coronary thrombolysis in perspective", Eds: B.E. Sobel and D. Collen, Marcel Dekker Inc, New York, N.Y. 1993, p. 303-316.
62. Lijnen H.R., Collen D.  
Molecular interactions between tissue-type plasminogen activator and plasminogen.  
In: "Proteolytic enzymes in coagulation, fibrinolysis and complement activation", Eds.: Lorand L., Mann K.G.  
*Meth. Enzymol.* 223, 197-206, 1993.
63. Collen D., Lijnen H.R.  
Fibrinolysis and the control of hemostasis.  
In: "Molecular Basis of Blood Diseases", Second Edition, Eds: Stamatoyannopoulos G, Nienhuis A.W., Majerus P.W., Varmus H. W.B. Saunders Co., Philadelphia, PA, 1993, p. 725-752.
64. Collen D., Lijnen H.R.  
Thrombolytic agents.  
In: "Cardiovascular Pharmacology and Therapeutics". Eds.: B.N. Singh, V.J. Dzau, P. Vanhoutte, R.L. Woosley. Churchill Livingstone, New York 1993, p. 267-279.

65. Collen D., Verstraete M.  
Pharmacology of thrombolytic drugs.  
In: "The Heart, Eight Edition". Eds.: Schlant R.C., Alexander R.W. Mc Graw-Hill Inc.,  
New York 1993, p. 1327-1337.
66. Vaughan D.E., Collen D., Gold H.K.  
Experimental models for thrombolysis.  
In: "Thrombosis and hemorrhage". Eds.: J. Loscalzo and A.I. Shafer. Blackwell  
Scientific Publ., Oxford, 1994, p. 395-404.
67. Collen D., Lijnen H.R.  
On the future of thrombolytic therapy for acute myocardial infarction.  
Am. J. Cardiol. 72, 46G-50G, 1993.
68. Dewerchin M., Collen D.  
Antiplatelet antibody/plasminogen activator conjugates for targeted thrombolysis.  
In: "Monoclonal Antibodies in Cardiovascular Diseases", Eds: Khaw B.A., Naruba J.,  
Strauss H.W., Lea and Fabiger, Philadelphia 1994, p 198-205.
69. Lijnen H.R., Collen D.  
Development of new fibrinolytic agents.  
In: "Haemostasis and Thrombosis, 3rd Edition", Eds.: Bloom A.L., Forbes C.D.,  
Thomas D.P., Tuddenham E.G.D., Churchill Livingstone, Edinburgh 1994, p 625-637.
70. Lijnen H.R., Collen D.  
Interactions between heparin and fibrinolysis.  
In "LMW heparin in prophylaxis and therapy of thromboembolic diseases" Ed. H.  
Bounameaux. Marcel Dekker Inc., New York 1994, p. 143-167.
71. Collen D.  
Is there an optimal thrombolytic regimen ?  
In: "Clinical trials in thrombolysis, revisited", Ed: W.J. Rogers.  
Coron. Art. Dis. 5, 287-291, 1994.
72. Collen D., Lijnen H.R.  
Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?  
Blood 84, 680-686, 1994.
73. Lijnen H.R., Bachmann F., Collen D., Ellis V., Pannekoek H., Rijken D.C., Thorsen S.  
Mechanisms of plasminogen activation.  
J. Int. Med. 236, 415-424, 1994.
74. Collen D., de Bono D.P., Lijnen H.R., Pannekoek H.  
Development of novel thrombolytic agents.  
J. Int. Med. 236, 433-437, 1994

75. Carmeliet P., Mulligan R.C., Collen D.  
Transgenic animals as tools for the study of fibrinolysis *in vivo*.  
J. Int. Med. 236, 455-459, 1994.
76. Holvoet P., Collen D.  
Oxidized lipoproteins in atherosclerosis and thrombosis.  
FASEB J 8, 1279-1284, 1994.
77. Collen D., Lijnen H.R.  
New generation thrombolytic agents.  
In: "The modern era of coronary thrombolysis " Ed: R.C. Becker, Kluwer Acad. Publ.,  
Boston, 1994, p. 15-25.
- 77.b. Carmeliet P., Collen D. Evaluation of the plasminogen/plasmin system in transgenic  
mice. Fibrinolysis 8, 269-276, 1994.
78. Lijnen H.R., Collen D.  
Molecular and Cellular basis of fibrinolysis.  
In: "Hematology: Basic principles and practice 2nd Ed", Ed: R. Hoffman, E.J. Benz Jr.,  
S.J. Shattil, B. Furie, H.J. Cohen and L.E. Silberstein.  
Churchill Livingstone, New York 1995, p. 1588-1596.
79. Lijnen H.R., Collen D.  
Vascular endothelial cell function and thrombosis.  
In: "Cardiovascular Medicine", Eds.: J.T. Willerson, J.N. Cohn, Churchill Livingstone,  
New York 1995, p. 1080-1090.
80. Carmeliet P., Bouché A., De Clercq C., Janssen S., Pollefeyt S., Wyns S., Mulligan  
R.C., Collen D.  
Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type  
plasminogen activator, and plasminogen activator inhibitor-1 genes in mice.  
Ann. N.Y. Acad. Sci. 748, 367-382, 1995.
81. Collen D., Lijnen H.R.  
The fibrinolytic system: implications for thrombolytic therapy.  
In: "Acute Coronary Care", Eds.: Califf R.M., Mark D.B., Wagner G.S., Mosby, St.  
Louis 1995, p. 85-95.
82. Collen D., Lijnen H.R.  
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.  
Thromb. Haemost. 74, 167-171, 1995.
83. Lijnen H.R., Collen D.  
Fibrinolytic agents: mechanisms of activity and pharmacology.  
Thromb. Haemost. 74, 387-390, 1995.

84. Carmeliet P., Collen D.  
Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system.  
*Thromb. Haemost.* 74, 429-436, 1995.
85. Vanderschueren S., Lijnen H.R., Collen D.  
Properties of staphylokinase and its potential as a thrombolytic agent.  
*Fibrinolysis* 9 (Suppl. 1), 87-90, 1995.
86. Carmeliet P., Collen D.  
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.  
*FASEB J.* 9, 934-938, 1995.
87. Holvoet P., Collen D.  
Lipid lowering and enhancement of fibrinolysis with niacin. Editorial.  
*Circulation* 92, 698-699, 1995.
88. Verstraete M., Lijnen H.R., Collen D.  
Thrombolytic agents in development.  
*Drugs* 50, 29-42, 1995.
89. Carmeliet P., Collen D.  
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis.  
*Trends Cardiovasc. Med.* 5, 117-122, 1995.
90. Collen D., Lijnen H.R., Vanderschueren S.  
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.  
*Verhand. Koninkl. Acad. Geneesk. België* 57, 183-198, 1995.
91. Collen D., Lijnen H.R.  
Thrombolytic agents.  
In: "Molecular Cardiovascular Medicine". Ed.: E. Haber, Scientific American, New York 1995, p 133-143.
92. Verstraete M., Collen D.  
Optimising thrombolytic therapy in elderly patients with acute myocardial infarction.  
*Drugs Aging* 8, 17-22, 1996.
93. Collen D.  
Fibrin-selective thrombolytic therapy for acute myocardial infarction.  
*Circulation* 93, 857-865, 1996.
94. Vanderschueren S., Collen D.  
The next generation of thrombolytics  
In: "Emerging drugs: the prospect for improved medicines". Ashley Publications Ltd 1996, p. 49-64.

95. Carmeliet P., Collen D.  
Evaluation of the role of the fibrinolytic system in transgenic animals.  
In: "Vascular Control of Haemostasis". V.W.M. van Hinsbergh (Ed.), Harwood Acad. Publ., Amsterdam 1996, p. 247-256.
96. Lijnen H.R., Collen D.  
Staphylokinase, a fibrin-specific bacterial plasminogen activator.  
Fibrinolysis 10, 119-126, 1996.
97. Lijnen H.R., Stump D.C., Collen D.  
Single-chain urokinase-type plasminogen activator (prourokinase). In: "Cardiovascular drug therapy. Second Edition", Messerli F.H. (Ed.), Saunders Co, Philadelphia 1996, p 1578-1587.
98. Collen D., Vanderschueren S., Van de Werf F.  
Fibrin-selective thrombolytic therapy with recombinant staphylokinase.  
Haemostasis 26, S4, 294-300, 1996.
- 98b. Vanderschueren S., Collen D., Van de Werf F.  
Current clinical experience with staphylokinase in arterial thrombosis.  
J. Thromb. Thrombol. 3, 297-300, 1996.
99. Carmeliet P., Collen D.  
Targeted gene manipulation and transfer of the plasminogen and coagulation system in mice.  
Fibrinolysis 10, 195-213, 1996.
100. Lijnen H.R., Collen D.  
Impaired fibrinolysis and the risk for coronary heart disease. Editorial.  
Circulation 94, 2052-2054, 1996.
101. Carmeliet P., Collen D.  
Genetic analysis of the plasminogen and coagulation system in mice.  
Haemostasis 26 suppl 4, 132-153, 1996.
102. Carmeliet P., Collen D.  
Gene manipulation and transfer of the plasminogen and coagulation system in mice.  
Sem. Thromb. Haemost. 22, 525-542, 1996.
103. Carmeliet P., Collen D.  
Insights into vascular biology via targeted gene inactivation and adenovirus-mediated gene transfer of the plasminogen system.  
In: "Coronary restenosis. From genetics to therapeutics". Ed.: G.Z. Feuerstein. Marcel Dekker Inc., New York 1997, p. 225-240.
104. Lijnen H.R., Collen D.  
Endothelium in hemostasis and thrombosis.  
Progr. Cardiovasc. Dis. 39, 343-350, 1997.

105. Carmeliet P., Moons L., Dewerchin M., Mackman N., Luther T., Breier G., Ploplis V., Müller M., Nagy A., Plow E., Gerard R., Edgington T., Risau W., Collen D.  
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.  
Ann. N.Y. Acad. Sci. 811, 191-206, 1997.
106. Carmeliet P., Collen D.  
Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis.  
Curr. Opin. Lipidol. 8, 118-125, 1997.
107. Collen D.  
Thrombolytic therapy.  
Thromb. Haemost. 78, 742-746, 1997.
108. Vanderschueren S., Van de Werf F., Collen D.  
Recombinant staphylokinase for thrombolytic therapy.  
In: "New therapeutic agents in thrombosis and thrombolysis". Ed.: A.A. Sasahara, J. Loscalzo. Marcel Dekker Inc., New York 1997, p. 591-602.
109. Holvoet P., Collen D.  
Thrombosis and atherosclerosis.  
Curr. Opin. Lipidol. 8, 320-328, 1997.
110. Vanderschueren S., Van de Werf F., Collen D.  
Recombinant staphylokinase for thrombolytic therapy.  
Fibrinol. Proteol. 11, Suppl 2, 39-44, 1997.
111. Gerard R.D., Collen D.  
Adenovirus gene therapy for hypercholesterolemia, thrombosis and restenosis.  
Cardiovasc. Res. 35, 451-458, 1997.
112. Carmeliet P., Collen D.  
Genetic analysis of blood vessel formation. Role of endothelial versus smooth muscle cells.  
Trends Cardiovasc. Med. 7, 271-281, 1997.
113. Carmeliet P., Collen D.  
Molecular analysis of blood vessel formation and disease.  
Am. J. Physiol. (Heart and Circulatory Physiology) 273; H2091-H2104, 1997.
114. Collen D.  
Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.  
Nature Med. 4, 279-284, 1998.



115. Lijnen H.R., Collen D., Verstraete M.  
Thrombolytic agents.  
In: "Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Second Edition", Eds.: Verstraete M., Fuster V., Topol E.J., Lippincott-Raven Publishers, Philadelphia 1998; pp. 301-320.
116. Holvoet P., Collen D.  
Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis.  
Atherosclerosis 137, S33-S38, 1998.
117. Carmeliet P., Moons L., Collen D.  
Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis.  
Cardiovasc. Res. 39, 8-33, 1998.
118. Carmeliet P., Collen D.  
Vascular development and disorders: Molecular analysis and pathogenic insights.  
Kidney Int. 53, 1519-1549, 1998.
119. Lijnen H.R., Collen D.  
t-Plasminogen activator.  
In: "Handbook of proteolytic enzymes" Ed.: A.J. Barrett. 1998, pp. 184-190.
120. Carmeliet P., Collen D.  
Molecules in focus: Tissue factor.  
Int. J. Biochem. Cell Biol. 30, 661-667, 1998.
121. Collen D.  
Engineered staphylokinase variants with reduced immunogenicity.  
Fibrinol. Proteol. 12 (Suppl. 2): 59-65, 1998.
122. Carmeliet P., Collen D.  
Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system.  
Thromb. Res. 91, 255-285, 1998.
- 122.b. Lijnen H.R., Collen D.  
Recent advances in thrombolytic therapy.  
In: "Lectures 15<sup>th</sup> International Congress on Thrombosis, Antalya, Turkiye, October 16-21, 1998.
123. Collen D.  
The plasminogen (fibrinolytic) system.  
Marian Barnhart Lecture.  
Thromb. Haemost. 82, 259-270, 1999.
124. Carmeliet P., Collen D.  
New developments in the molecular biology of coagulation and fibrinolysis.  
In: "Antithrombotics". A.C.G. Uprichard, K.P. Gallagher (eds.). Springer-Verlag, Berlin, Germany 1999, p. 41-76.

125. Carmeliet P., Collen D.  
Molecular analysis of vascular development and disorders.  
In: "Cardiovascular Specific Gene Expression". P.A. Doevendans, R.S. Reneman, M. van Bilsen (eds.). Kluwer Academic Publishers, Dordrecht, The Netherlands 1999, p. 193-225.
126. Carmeliet P., Collen D.  
Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development.  
In: "Vascular Growth Factors and Angiogenesis" L. Claesson-Welsh (ed.), Springer-Verlag, Berlin, Germany 1999, p. 133-158.
127. Lijnen H.R., Collen D.  
Molecular and Cellular Basis.  
In: "Hematology: Basic Principles and Practice", 3<sup>rd</sup> Edition, Eds: R. Hoffman et al., Churchill Livingstone, Philadelphia, 1999, pp. 1804-1814.
128. Lijnen H.R., Collen D.  
Matrix metalloproteinase system deficiencies and matrix degradation.  
Thromb. Haemost. 82, 837-845, 1999.
129. Lijnen H.R., Collen D.  
Basic aspects of fibrinolysis and thrombolysis.  
In: Update in Intensive Care and Emergency Medicine, vol. 32. Coronary Circulation and Myocardial Ischemia (Pinsky M.R., Artigas A., Dhainaut J.F., Eds.), Springer-Verlag, Heidelberg, 62-71, 2000.
130. Carmeliet P., Collen D.  
Transgenic mouse models in angiogenesis and cardiovascular disease.  
J. Pathol. 190, 387-405, 2000.
131. Collen D., Lijnen H.R.  
Recent developments in thrombolytic therapy.  
Fibrinol. Proteol. 14, 66-72, 2000.
132. Carmeliet P., Collen D.  
Molecular basis of angiogenesis: role of VEGF and VE-cadherin.  
Ann. N.Y. Acad. Sci. 902, 249-264, 2000.
133. Lijnen H.R., Collen D.  
Molecular basis of thrombolytic therapy.  
J. Nucl. Cardiol. 7, 373-381, 2000.
134. Collen D., Sobel B.  
Letter to the Editor. Intracranial haemorrhage with bolus thrombolytic agents.  
Lancet 356, 1848, 2000.

135. Luttun A., Dewerchin M., Collen D., Carmeliet P.  
The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.  
*Curr. Atheroscl. Rep.* 2, 407-416, 2000.
136. Lijnen H.R., Arnout J., Collen D.  
Vascular endothelial cell function and thrombosis.  
In: *Cardiovascular Medicine*. 2<sup>nd</sup> Edition. J.T. Willerson, J.N. Cohn (Eds.), Churchill Livingstone, New York, 1311-1323, 2000.
137. Lijnen H.R., Collen D.  
Regolazione del sistema fibrinolitico.  
In: *Trombolisi Yearbook 2000*. G. Agnelli (Ed.), Excerpta Medica, Milano, 1-44, 2000.
138. Lijnen H.R., Collen D.  
New thrombolytic strategies and agents.  
*Hematologica* 85, Suppl. 2, 106-109, 2000.
139. Lijnen H.R., Collen D.  
New thrombolytic strategies and agents.  
*Revista Iberoamericana de Trombosis y Hemostasia* 13, Suppl. 1, 45-48, 2000.
140. Lijnen H.R., Collen D.  
Fibrinolysis and the control of hemostasis.  
In: *Molecular Basis of Blood Diseases*, 3rd Edition. G. Stamatoyannopoulos, P.W. Majerus, R.M. Perlmutter, H. Varmus (Eds.), W.B. Saunders Company, Philadelphia, 740-763, 2001.
141. Lijnen H.R., Collen D.  
Staphylokinase.  
In: "Fibrinolytics and antifibrinolytics. Handbook of experimental pharmacology". F. Bachmann (Ed.), Springer-Verlag, Berlin, 425-449, 2001.
142. Collen D.  
Fibrin-selective thrombolytic therapy of acute myocardial infarction.  
In: "Fibrinolytics and antifibrinolytics. Handbook of experimental pharmacology". F. Bachmann (Ed.), Springer-Verlag, Berlin, 209-229, 2001.
143. Conway E.M., Collen D., Carmeliet P.  
Molecular mechanisms of blood vessel growth.  
*Cardiovasc. Res.* 49, 507-521, 2001.
144. Chuah M.K.L., Collen D., VandenDriessche T.  
Gene therapy for hemophilia.  
*J. Gene Med.* 3, 3-20, 2001.

145. Armstrong P.W., Collen D.  
Fibrinolysis for acute myocardial infarction: Current status and new horizons for pharmacological reperfusion. Part 1  
*Circulation* 103, 2862-2866, 2001.
146. Armstrong P.W., Collen D.  
Fibrinolysis for acute myocardial infarction: Current status and new horizons for pharmacological reperfusion. Part 2  
*Circulation* 103, 2987-2992, 2001.
147. Collen D., Lijnen H.R.  
Tissue-type plasminogen activator: helping patients with acute myocardial infarction. *Recombinant Protein Drugs* (P. Buckel, Ed.), Birkhäuser Publishing Ltd., Basel, Switzerland, pp. 107-126, 2001.
148. Collen D.  
Editorial. Revival of plasmin as a therapeutic agent?  
*Thromb. Haemost.* 86, 731-732, 2001.
149. VandenDriessche T., Collen D., Chuah M.K.L.  
Viral vector-mediated gene therapy for hemophilia.  
*Curr. Gene Ther.* 1, 301-315, 2001.
150. De Geest B., Collen D.  
Antibodies against oxidized LDL for non-invasive diagnosis of atherosclerotic vascular disease. Editorial  
*Eur. Heart J.* 22, 1517-1518, 2001.
151. Collen D.  
Ham-Wasserman Lecture: Role of the plasminogen system in fibrin-homeostasis and tissue remodelling.  
*Hematology*, 1, 1-9, 2001.
152. VandenDriessche T., Naldini L., Collen D., Chuah M.K.L.  
Oncoretroviral and lentiviral vector-mediated gene therapy.  
*Meth. Enzymol.* 346, 573-589, 2002.
153. Angelillo-Scherrer A., Collen D., Carmeliet P.  
Gas6, une nouvelle protéine de l'hémostase.  
*Hématologie* 8, 173-180, 2002.
154. VandenDriessche T., Collen D., Chuah M.K.L.  
Gene therapy for hemophilia A: Immune consequences of viral-vector mediated Factor VIII gene transfer.  
*Haematologica* 87, 93-100, 2002.

155. Sinnaeve P., Lijnen H.R., Collen D.  
Recombinant staphylokinase for thrombolytic therapy.  
In: Therapeutic Agents for Thrombosis and Thrombolysis, A.A. Sasahara, J. Loscalzo J. (eds.), Marcel Dekker, New York, NY, pp 593-604, 2003.
156. Lijnen H.R., Collen D.  
Fibrinolytic system and its disorders.  
In: Blood: Principles and Practice of Hematology. 2<sup>nd</sup> Edition. R.I. Handin, S.E. Lux, T.P. Stossel (Eds.), Lippincott Williams & Wilkins, Philadelphia, USA, pp. 1249-1274, 2003.
157. Armstrong P.W., Collen D., Antman E.  
Fibrinolysis for acute myocardial infarction: the future is here and now.  
*Circulation* 107, 2533-2537, 2003.
158. VandenDriessche T., Collen D., Chuah M.K.L.  
Gene therapy for the hemophilias.  
*J. Thromb. Haemost.* 1, 1550-1558, 2003.
159. Moreadith R.W., Collen D.  
Clinical Development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction  
*Adv. Drug Deliv. Rev.* 55, 1337-1345, 2003.
160. Collen D., Carmeliet P., Brunaud C., Schoonjans L.  
Cardiovascular stem cell research in interactions between the university and industry  
*Verh. K. acad. Geneesk. Belg.* 65, 281-282, 2003.
161. Vandendriessche T., Collen D., Chuah MK.  
Biosafety of onco-retroviral vectors.  
*Curr. Gene Ther.* 3, 501-515, 2003.
162. Chuah MK., Collen D., Vandendriessche T.  
Biosafety of adenoviral vectors  
*Curr. Gene Ther.* 3, 527-543, 2003.
163. Chuah M.K., Collen D., VandenDriessche T.  
Clinical gene transfer studies for hemophilia a.  
*Semin. Thromb. Hemost.* 30, 249-256, 2004.
164. Van Damme A., Chuah M.K., Collen D., VandenDriessche T.  
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.  
*Semin. Thromb. Hemost.* 30, 185-195, 2004.
165. Thorrez L., VandenDriessche T., Collen D., Chuah M.K.  
Preclinical gene therapy studies for hemophilia using adenoviral vectors.  
*Semin. Thromb. Hemost.* 30, 173-183, 2004.

166. Collen D., Lijnen H.R.  
Tissue-type plasminogen activator: a historical perspective and personal account.  
*J. Thromb. Haemost.* 2, 541-546, 2004.
167. Lijnen H.R., Collen D.  
t-Plasminogen activator.  
In: "Handbook of Proteolytic Enzymes". 2<sup>nd</sup> Edition. Barrett A.J., .... (eds.), Academic Press, London 2004, pp. 1684-1689.
168. Chuah M.K., Collen D., Vandendriessche T.  
Preclinical and clinical gene therapy for haemophilia.  
*Haemophilia* 10, 119-125, 2004.
169. Collen D., Lijnen H.R.  
Thrombolytic agents.  
*Thromb. Haemost.* 93, 627-630, 2005.
170. Collen D., Hoylaerts M.F.  
Relationship between inflammation and venous thromboembolism as studied by microparticle assessment in plasma.  
*J. Am. Coll. Cardiol.* 45, 1472-1473, 2005.
171. Rossignol P., Luttun A., Martin-Ventura J.L., Lupu F., Carmeliet P., Collen D., Anglès-Cano E., Lijnen H.R.  
Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques.  
*J. Thromb. Haemost.* 4, 664-670, 2006.
172. Collen D., Lijnen H.R.  
The Tissue-Type Plasminogen Activator Story.  
*Arterioscl. Thromb. Vasc. Biol.* 29, 1151-1155, 2009.

### III. Publications retirement

1. Lijnen H.R.  
Retirement of Désiré Collen.  
J. Thromb. Haemost. 7, 2-3, 2009.
2. Rijken D.C., Lijnen H.R.  
New insights into the molecular mechanisms of the fibrinolytic system.  
J. Thromb. Haemost. 7, 4-13, 2009.
3. Van de Werf F.J., Topol E.J., Sobel B.E.  
The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.  
J. Thromb. Haemost. 7, 14-20, 2009.
4. Loges S., Roncal C., Carmeliet P.  
Development of targeted angiogenic medicine.  
J. Thromb. Haemost. 7, 21-23, 2009.

#### IV. US Patents

1. Collen D.  
Purification of antiserum for thrombosis test  
US 4,180,437, December 25, 1979
2. Collen D.  
Antiplasmin and antiserum  
US 4,198,335, April 15, 1980
3. Collen D.  
Determination of heparin in blood plasma  
US 4,202,872, May 13, 1980
4. Collen D.  
Thrombosis-test  
US 4,216,291, August 5, 1980
5. Collen D.  
Antiplasmin and antiserum  
US 4,346,029, August 24, 1982
6. Collen D.  
Novel composition of matter of antithrombin III bound to a heparin fragment  
US 4,623,718, November 18, 1986
7. Collen D., Rijken D., Matsuo O.  
Plasminogen activator and pharmaceutical composition having thrombolytic activity  
US 4,752,603, June 21, 1988
8. Collen D.  
Pharmaceutical composition having thrombolytic activity  
US 5,174,994, December 29, 1992
9. Gold H., Coller B., Collen D.  
Method of treatment for myocardial infarction  
US 5,275,812, January 4, 1994
10. Collen D., Stassen JM, Lijnen H.  
Use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thrombosis  
US 5,336,495, August 9, 1994
11. Collen D.  
Staphylokinase derivatives  
US 5,695,754, December 9, 1997
12. Collen D.  
Identification, production and use of new staphylokinase derivatives with reduced immunogenicity  
US 5,951,980, September 14, 1999



13. Holvoet P., Collen D.  
Detection and determination of the stages of coronary artery disease  
US 6,309,888, October 30, 2001
14. Collen D.  
Staphylokinase derivatives with cysteine substitutions  
US 6,383,483, May 7, 2002
15. Varenne O., Collen D., Janssens S.  
Gene therapeutic treatment of blood vessel associated disorders  
US 6,398,757, June 4, 2002
16. Janssens S., Bloch K., Collen D.  
Method of inducing vasodilation and treating pulmonary hypertension using adenoviral-mediated transfer of the nitric oxide synthase gene  
US 6,720,309, April 13, 2004
17. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 6,727,102, April 27, 2004
18. Carmeliet P., Collen D.  
Method of improving ischemic muscle function by administering placental growth factor  
US 7,105,168, September 12, 2006
19. Collen D.  
Staphylokinase derivatives with polyethyleneglycol  
US 6,902,733, June 7, 2005
20. Nagai N., Collen D.  
Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke  
US 6,946,438, September 20, 2005
21. Holvoet P., Collen D.  
Detection and determination of the stages of coronary artery disease  
US 7,166,469, January 23, 2007
22. Carmeliet P., Collen D., Oosthuysen B.  
Use of VEGF and homologues to treat neuron disorders  
US 7,226,908, June 5, 2007
23. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 7,229,775, June 12, 2007
24. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 7,229,776, June 12, 2007

25. Conway E., Collen D.  
Lectin-like domain of thrombomodulin and its therapeutic use  
US 7,341,992, March 11, 2008
26. Carmeliet P., Collen D., Bouillon R., Carmeliet G.  
Placental growth factor as a target for the treatment of osteoporosis  
US 7,357,929, April 15, 2008
27. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 7,378,250, May 27, 2008
28. Collen D. Nagai N., Laroche Y.  
Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell  
US 7,445,775, November 4, 2008
29. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 7,390,627, June 24, 2008
30. Carmeliet P., Collen D., De Falco S., Menotti R.  
Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage  
US 7,482,004, January 27, 2009
31. Holvoet P., Collen D.  
Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins  
US 7,579,159, August 25, 2009
32. Carmeliet P., Collen D., Oosthuysen B.  
Use of VEGF and homologues to treat neuron disorders  
US 7,592,314, September 22, 2009
33. Holvoet P., Collen D.  
Detection and determination of the stages of coronary artery disease  
US 7,604,952, October 20, 2009
34. Eriksson U., Li X., Carmeliet P., Collen D.  
Stimulation of vascularization with VEGF-B-186  
US 7,709,450, May 4, 2010
35. Carmeliet P., Collen D.  
Use of placental growth factor for treating ischemic muscle disease  
US 7,727,971, June 1, 2010
36. Stassen JM., Carmeliet P., Collen D.  
Anti-PLGF antibody  
US 7,875,704, January 25, 2011

37. Carmeliet P., Collen D., Oosthuysen B.  
Use of VEGF and homologues to treat neuron disorders  
US 7,888,322, February 15, 2011
38. Stassen JM., Carmeliet P., Collen D.  
Anti-angiogenic therapy  
US 8,758,748, June 24, 2014
39. Stassen JM., Carmeliet P., Collen D.  
Anti-angiogenic therapy  
US 9,085,617, July 21, 2015